

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/007586

International filing date: 09 March 2005 (09.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/551,646
Filing date: 09 March 2004 (09.03.2004)

Date of receipt at the International Bureau: 29 April 2005 (29.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1311307

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 20, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/551,646

FILING DATE: *March 09, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/07586*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 C.F.R. § 1.53(c).

	Docket Number	21085.0072U1	Type a Plus Sign (+) inside this box	+															
INVENTOR(s)																			
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (City and Either State or Foreign Country)																
Martin	Michael		369 Old Cahaba Trail, Helena, AL 35080																
TITLE OF INVENTION (500 characters max)																			
METHODS AND COMPOSITIONS RELATED TO REGULATION OF CYTOKINE PRODUCTION BY GLYCOGEN SYNTHASE KINASE 3 (GSK-3)																			
CORRESPONDENCE ADDRESS																			
Tina W. McKeon Customer Number 23859																			
ENCLOSED APPLICATION PARTS (Check All That Apply)																			
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%;"><input checked="" type="checkbox"/> Provisional Application Title Page</td> <td style="width: 20%; text-align: right;"><i>Number of Pages</i></td> <td style="width: 30%; text-align: right;">[01]</td> </tr> <tr> <td><input checked="" type="checkbox"/> Specification (includes Description, Claims, & Abstract)</td> <td style="text-align: right;"><i>Number of Pages</i></td> <td style="text-align: right;">[56]</td> </tr> <tr> <td><input checked="" type="checkbox"/> Drawing(s)</td> <td style="text-align: right;"><i>Number of Sheets</i></td> <td style="text-align: right;">[10]</td> </tr> <tr> <td><input checked="" type="checkbox"/> Authorization to Treat Reply Requesting Extension of Time as Incorporating Petition for Extension of Time</td> <td></td> <td></td> </tr> <tr> <td><input checked="" type="checkbox"/> Other (specify): Sequence Listing</td> <td style="text-align: right;"><i>Number of Sheets</i></td> <td style="text-align: right;">[05]</td> </tr> </table>					<input checked="" type="checkbox"/> Provisional Application Title Page	<i>Number of Pages</i>	[01]	<input checked="" type="checkbox"/> Specification (includes Description, Claims, & Abstract)	<i>Number of Pages</i>	[56]	<input checked="" type="checkbox"/> Drawing(s)	<i>Number of Sheets</i>	[10]	<input checked="" type="checkbox"/> Authorization to Treat Reply Requesting Extension of Time as Incorporating Petition for Extension of Time			<input checked="" type="checkbox"/> Other (specify): Sequence Listing	<i>Number of Sheets</i>	[05]
<input checked="" type="checkbox"/> Provisional Application Title Page	<i>Number of Pages</i>	[01]																	
<input checked="" type="checkbox"/> Specification (includes Description, Claims, & Abstract)	<i>Number of Pages</i>	[56]																	
<input checked="" type="checkbox"/> Drawing(s)	<i>Number of Sheets</i>	[10]																	
<input checked="" type="checkbox"/> Authorization to Treat Reply Requesting Extension of Time as Incorporating Petition for Extension of Time																			
<input checked="" type="checkbox"/> Other (specify): Sequence Listing	<i>Number of Sheets</i>	[05]																	

METHOD PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (Check One)

- ☒ Applicant claims small entity status. See 37 CFR § 1.27.
- ☒ A Credit Card Payment Form PTO-2038 is enclosed to cover the filing fees.
- ☐ A check or money order is enclosed to cover the filing fees.
- ☐ The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number _____.
- ☒ The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 14-0629.

FILING FEE AMOUNT

\$ 80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes. The name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

Signature



Date

March 9, 2004

Typed or Printed Name:


Tina W. McKeon

Registration No.

43,791

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail, Label No. EL 992076753US in an envelope addressed to: **MAIL STOP PROVISIONAL PATENT APPLICATION**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.



3/9/04

Michael Laird

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Michael MARTIN)
Application No. Unassigned)
Filing Date: Concurrently)
For: METHODS AND COMPOSITIONS)
RELATED TO REGULATION)
CYTOKINE PRODUCTION BY)
GLYCOGEN SYNTHASE KINASE 3)
(GSK-3))

AUTHORIZATION TO TREAT REPLY REQUIRING EXTENSION OF TIME
AS INCORPORATING PETITION FOR EXTENSION OF TIME

Mail Stop PROVISIONAL PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:


Pursuant to 37 C.F.R. § 1.136(a)(3), the Commissioner is hereby requested and authorized to treat any concurrent or future reply in the above-identified application, requiring a petition for an extension of time for its timely submission, as incorporating a petition for extension of time for the appropriate length of time.

ATTORNEY DOCKET NO. 21085.0072U1
PATENT

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Tina W. McKeon
Registration No. 43,791

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail, Label No. EL 992076753 US, in an envelope addressed to: Mail Stop **PROVISIONAL PATENT APPLICATION**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.



Michael Laird

3/9/04

Date

EXPRESS MAIL NO. EL 992076753US
ATTORNEY DOCKET NO. 21085.0072U1
PROVISIONAL PATENT

5

10

**PROVISIONAL
APPLICATION
FOR
UNITED STATES LETTERS PATENT
FOR**

15

**METHODS AND COMPOSITIONS RELATED TO REGULATION OF
CYTOKINE PRODUCTION BY GLYCOGEN SYNTHASE KINASE 3 (GSK-3)**

20

BY

**Michael Martin, 369 Old Cahaba Trail, Helena, AL 35080, citizen of the United
State of America.**

25

30

**METHODS AND COMPOSITIONS RELATED TO REGULATION OF
CYTOKINE PRODUCTION BY GLYCOGEN SYNTHASE KINASE 3 (GSK-3)**

5

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

This invention relates generally to a method of controlling the inflammatory response. The invention has broad applicability in inflammatory diseases or processes to control or alter inflammation.

BACKGROUND ART

Inflammation is a complex stereotypical reaction of the body expressing the response to damage of cells and vascularized tissues. The discovery of the detailed processes of inflammation has revealed a close relationship between inflammation and the immune response. The main features of the inflammatory response are vasodilation, i.e. widening of the blood vessels to increase the blood flow to the infected area; increased vascular permeability, which allows diffusible components to enter the site; cellular infiltration by chemotaxis, or the directed movement of inflammatory cells through the walls of blood vessels into the site of injury; changes in biosynthetic, metabolic, and catabolic profiles of many organs; and activation of cells of the immune system as well as of complex enzymatic systems of blood plasma.

There are two forms of inflammation, acute and chronic. Acute inflammation can be divided into several phases. The earliest, gross event of an inflammatory response is temporary vasoconstriction, i.e. narrowing of blood vessels caused by contraction of smooth muscle in the vessel walls, which can be seen as blanching (whitening) of the skin. This is followed by several phases that occur over minutes, hours and days later. The first is the acute vascular response, which follows within seconds of the tissue

ATTORNEY DOCKET NO. 21085.0072U1

injury and lasts for several minutes. This results from vasodilation and increased capillary permeability due to alterations in the vascular endothelium, which leads to increased blood flow (*hyperemia*) that causes redness (*erythema*) and the entry of fluid into the tissues (*edema*).

5 The acute vascular response can be followed by an acute cellular response, which takes place over the next few hours. The hallmark of this phase is the appearance of granulocytes, particularly neutrophils, in the tissues. These cells first attach themselves to the endothelial cells within the blood vessels (margination) and then cross into the surrounding tissue (diapedesis). During this phase erythrocytes may also leak
10 into the tissues and a hemorrhage can occur. If the vessel is damaged, fibrinogen and fibronectin are deposited at the site of injury, platelets aggregate and become activated, and the red cells stack together in what are called “rouleau” to help stop bleeding and aid clot formation. The dead and dying cells contribute to pus formation. If the damage is sufficiently severe, a chronic cellular response may follow over the next few days. A
15 characteristic of this phase of inflammation is the appearance of a mononuclear cell infiltrate composed of macrophages and lymphocytes. The macrophages are involved in microbial killing, in clearing up cellular and tissue debris, and in remodeling of tissues.

Chronic inflammation is an inflammatory response of prolonged duration - weeks, months, or even indefinitely - whose extended time course is provoked by
20 persistence of the causative stimulus to inflammation in the tissue. The inflammatory process inevitably causes tissue damage and is accompanied by simultaneous attempts at healing and repair. The exact nature, extent and time course of chronic inflammation is variable, and depends on a balance between the causative agent and the attempts of the body to remove it. Etiological agents producing chronic inflammation include: (i)
25 infectious organisms that can avoid or resist host defenses and so persist in the tissue for a prolonged period. Examples include *Mycobacterium tuberculosis*, *Actinomycetes*, and numerous fungi, protozoa and metazoal parasites. Such organisms are in general able to avoid phagocytosis or survive within phagocytic cells, and tend not to produce toxins

ATTORNEY DOCKET NO. 21085.0072U1

causing acute tissue damage. (ii) Infectious organisms that are not innately resistant but persist in damaged regions where they are protected from host defenses. An example is bacteria which grow in the pus within an undrained abscess cavity, where they are protected both from host immunity and from blood-borne therapeutic agents, e.g. antibiotics. Some locations are particularly prone to chronic abscess formation, e.g. bone, and pleural cavities. (iii) Irritant non-living foreign material that cannot be removed by enzymatic breakdown or phagocytosis. Examples include a wide range of materials implanted into wounds (wood splinters, grit, metals and plastics), inhaled (silica dust and other particles or fibers), or deliberately introduced (surgical prostheses, sutures, etc.) Also included are transplants. Dead tissue components that cannot be broken down may have similar effects, e.g. keratin squames from a ruptured epidermoid cyst or fragments of dead bone (sequestrum) in osteomyelitis. (iv) In some cases the stimulus to chronic inflammation may be a normal tissue component. This occurs in inflammatory diseases where the disease process is initiated and maintained because of an abnormality in the regulation of the body's immune response to its own tissues - the so-called auto-immune diseases. (v) For many diseases characterized by a chronic inflammatory pathological process the underlying cause remains unknown. An example is Crohn's disease.

Examples of chronic inflammatory diseases include tuberculosis, chronic cholecystitis, bronchiectasis, rheumatoid arthritis, Hashimoto's thyroiditis, inflammatory bowel disease (ulcerative colitis and Crohn's disease), silicosis and other pneumoconiosis, and implanted foreign body in a wound.

Activation of innate immunity and promotion of inflammation are common responses to replication incompetent adenoviruses (Ad) now being developed as vectors for gene therapy (Jooss, K. (2003) Gene Ther. 10:955-963; Zaiss, A.K. (2002) J. Virol. 76:4580-4590). The complement system is central to both innate immunity and inflammation (Walport, M.J. (2001) N Eng J Med 344:1058-1066 and 1140-1144). Because it is comprised of multiple membrane-bound and blood factors, the

ATTORNEY DOCKET NO. 21085.0072U1

complement system is of particular relevance in delivery of vectors administered intravenously. In fact, Cichon et al. showed complement was activated in a majority of human plasma samples when challenged with different adenoviral serotypes; complement activation was completely dependent on anti-Ad antibody (Cichon (2001) 5 Gene Ther 8:1794-1800).

The complement mediated inactivation is a multistep enzymatic cascade which finally results in formation of a membrane attack complex (MAC) mediating the perforation of membranes and subsequent lysis of the invading organism. It is either initiated by antigen-antibody complexes (classical pathway) or via an antibody 10 independent pathway which is activated by certain particular polysaccharides, viruses and bacteria (alternative pathway).

Human organs and cells themselves are protected to complement mediated lysis. This protection is achieved by expression of complement inactivation factors. So far, five human factors are known. CD35 (CR1) is released from the cells and acts mainly 15 extrinsically. In contrast, CD59, CD46 (MCP), CD55 (DAF) and HRF are integrated into the cellular membrane. CD46 (MCP) is a classical transmembrane protein while HRF, CD59 and CD55 are GPI-anchored. These factors can interrupt the complement cascade at two different stages: DAF, CR1 and MCP act at an early stage of both the alternative and the classical pathway. In contrast, CD59 and HRF inhibit the assembly of 20 the membrane attack complex, which is the final step of both pathways resulting in channel formation and lysis.

The early pro-inflammatory cascade can be initiated by endotoxin (also known as lipopolysaccharide, or LPS). LPS is one of the major constituents of the cell walls of gram-negative bacteria. Recognition of conserved microbial products, such as LPS, by 25 the innate immune system leads to a variety of signal transduction pathways. These signal transduction pathways mediate the induction and secretion of cytokines that can regulate the level and duration of an inflammatory response. The systemic inflammatory response that accompanies endotoxic shock (caused by triggers such as

the presence of LPS) is controlled by the levels of pro- and anti-inflammatory cytokines. Although the production of pro-inflammatory cytokines by cells of the innate immune system play an important role in mediating the initial host defense against invading pathogens (O'Neill, 2000), an inability to regulate the nature or duration
5 of the host's inflammatory response can often mediate detrimental host effects as observed in chronic inflammatory diseases. Additionally, in the early stages of sepsis, the host's inflammatory response is believed to be in a hyperactive state with a predominant increase in the production of pro-inflammatory cytokines that mediate host tissue injury and lethal shock (Cohen, 2002). In this regard, the ability to suppress pro-
10 inflammatory cytokines and/or enhance anti-inflammatory cytokines, i.e. IL-10, has been shown to severely reduce the toxic effects of endotoxin (Berg, 1995; Howard, 1993).

Past studies have identified that the phosphatidylinositol 3-kinase (PI3K) pathway can limit the production of TNF- α and IL-12 upon TLR-stimulation (Fukao, 2002; Fukao, 2002; Guha, 2002). Moreover, it has been demonstrated that the
15 utilization of the PI3K pathway by a TLR2-agonist resulted in enhanced IL-10 production whereas the levels of IL-12 were reduced (Martin, 2003).

However, there remains a distinct need in the art for methods and compositions capable of regulating cytokine production, thereby controlling inflammation and
20 associated disorders.

SUMMARY OF THE INVENTION

In accordance with the purpose(s) of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to a method of reducing the
25 severity of inflammation in a subject.

In another aspect, the invention relates to a method of reducing the severity of inflammation in a biological system.

In yet another aspect, the invention relates to a method of reducing the risk of inflammation in a recipient of an implantation or transplantation.

In yet another aspect, the invention relates to a composition used in the methods described herein.

5

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the
10 description, serve to explain the principles of the invention.

Figure 1 shows *E. coli* LPS mediates the activation of Akt and GSK-3 via the PI3K-Akt pathway in human peripheral blood monocytes. Human monocytes were pre-incubated with (A, B, C) medium only, 20 μ M LY294002, or Akt inhibitor for 60 to 90 min before stimulation with 1 μ g/ml of *E. coli* LPS. Control cells were pre-
15 treated (60 to 90 min) with culture media containing 0.01% DMSO (control vehicle for LY294002 and Akt inhibitor) in which no alterations in the phosphorylation of Akt (ser⁴⁷³) or GSK-3 β (ser⁹) were observed as compared to monocytes pre-treated with media only and stimulated with *E. coli* LPS (data not shown). To assess Akt (ser⁴⁷³) or GSK-3 (ser⁹) phosphorylation, 20 μ g of total cell lysate was resolved on LDS-
20 PAGE and probed with anti-phospho Akt Ser⁴⁷³ or anti-phospho GSK-3 (ser⁹) followed by ECL detection. Immunoblots were stripped and re-probed with an antibody to total p38 to ensure equal protein loading. Data are representative of 6 separate experiments.

Figure 2 shows the ability of *E. coli* to differentially modulate the levels of (A) IL-10 and (B) IL-12 p40 is mediated by inhibition of GSK-3. For cytokine
25 determination, human monocytes were pre-incubated with medium only, 20 μ M LY294002, 10 μ M SB216763, or 5 mM LiCl for 60 to 90 min. Control cells were pre-treated with vehicle 0.01% DMSO (control for LY294002, Akt inhibitor, or

SB216763) or 5 mM NaCl (control for LiCl) in which no significant effect on IL-10 or IL-12 p40 production was observed as compared to human monocytes pre-treated with media only (data not shown). Cell-free supernatants were collected 20 h after stimulation and assessed for (A) IL-10 and (B) IL-12 p40 production by ELISA. *** indicates significant differences ($P < 0.001$) compared to *E. coli* LPS stimulated cultures. Results represent the mean \pm SD of 8 separate experiments.

Figure 3 shows inhibition of GSK-3 differentially regulates the levels of pro-inflammatory and anti-inflammatory cytokine production upon TLR-stimulation of human PBMC. Human PBMC were pre-treated with the indicated concentrations of SB216763 for 60 to 90 min before the addition of a TLR2- (LTA), TLR4- (*E. coli* synthetic lipid A), TLR5- (flagellin), or TLR9- (CpG) agonist. The levels of (A) IL-1 β , (B) IFN- γ , (C) IL-12 p40, (D) IL-6 and (E) IL-10 were determined by ELISA. *, **, and *** indicate statistical significance at $P < 0.05$, $P < 0.01$, and $P < 0.001$, respectively, as compared to non-treated controls containing 0.01% DMSO. Results represent 8 separate experiments.

Figure 4 shows administration of the GSK-3 inhibitor SB216763 mediates protection against LPS lethality in mice when given (A) 2 h before or (B) 2 h after a LD₁₀₀ of LPS. Mice (sham-injected and LPS groups) were pre-treated with i.p. injection of 1 ml PBS containing 0.01% DMSO (vehicle control). SB216763-treated mice were administered 1 ml of PBS containing 30 μ M of SB216763. After 2 h, mice pre-treated with SB216763 (denoted LPS + SB216763) or vehicle (denoted LPS group) were given 150 μ g of LPS by i.p., injection. ** and *** indicate statistically significant differences at $P < 0.01$ and $P < 0.001$, respectively, as compared to LPS-treated group. Results represent the mean of 30 mice/group.

Figure 5 shows the GSK-3 inhibitor SB216763 suppresses the *in vivo* production of pro-inflammatory cytokine production including (A) IL-1 β , (B) IL-12 p40, and (C) IFN- γ whereas the levels of the anti-inflammatory cytokine (D) IL-10 are enhanced. SB216763-treated mice were given 1 ml of PBS containing 30 μ M of

ATTORNEY DOCKET NO. 21085.0072U1

SB216763. Sham-injected and LPS groups were given 1 ml of PBS containing vehicle (0.01% DMSO). After 2 h, mice pre-treated with SB216763 (denoted LPS + SB216763) or vehicle (denoted LPS group) were given 150 µg of LPS by i.p., injection. *** indicates statistically significant differences at $P < 0.001$, as compared to LPS-treated group. Results represent the mean \pm SD of 10 mice/group.

Figure 6 shows purified human CD4⁺ T cells were stimulated with plate-bound anti-CD3 (10 µg/ml) for 72 h in the presence or absence of the GSK-3 inhibitor SB216763. Supernatants were analyzed for Th1- (IFN- γ) and Th2- (IL-10) type cytokines by ELISA. Data demonstrates that inhibition of GSK-3 can suppress the production of inflammatory type cytokines, i.e. IFN- γ , whereas the levels of anti-inflammatory cytokines, i.e. IL-10, are significantly enhanced. *** indicates statistical significance at $P < 0.001$, as compared to anti-CD3 stimulated T cells in the absence of GSK-3 inhibition. Thus, inhibition of GSK-3 at the T cell level also suppresses inflammatory cytokines while increasing anti-inflammatory cytokine production. Moreover, inhibition of GSK-3 can enhance Th2-type immune responses while suppressing Th1-type responses.

DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the following detailed description of preferred embodiments of the invention and the Examples included therein and to the Figures and their previous and following description.

Definitions

As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a small molecule” includes mixtures of one or more small molecules, and the like.

ATTORNEY DOCKET NO. 21085.0072U1

Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will
5 be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

The terms “higher,” “increases,” “elevates,” or “elevation” refer to increases above basal levels, or as compared to a control. The terms “low,” “lower,” “inhibits,”
10 “inhibition,” “reduces,” or “reduction” refer to decreases below basal levels, or as compared to a control. For example, basal levels are normal *in vivo* levels prior to, or in the absence of, inflammation or the addition of an agent which causes inflammation.

The term “mediate” or “mediation” and “modulate” or “modulation” means to regulate, or control, in particular to increase, enhance, elevate, or alternatively to lower,
15 inhibit, or reduce. The terms “mediate” and “modulate” are used interchangeably throughout.

“Inflammation” or “inflammatory” is defined as the reaction of living tissues to injury, infection, or irritation. Anything that stimulates an inflammatory response is said to be inflammatory.

20 “Inflammatory disease” is defined as any disease state associated with inflammation. Examples of inflammatory disease include, but are not limited to, asthma, systemic lupus erythematosus, rheumatoid arthritis, reactive arthritis, spondylarthritis, systemic vasculitis, insulin dependent diabetes mellitus, multiple sclerosis, experimental allergic encephalomyelitis, Sjögren’s syndrome, graft versus host disease, inflammatory
25 bowel disease including Crohn’s disease, ulcerative colitis, and scleroderma.

Inflammatory diseases also includes autoimmune diseases such as myasthenia gravis, Guillain-Barré disease, primary biliary cirrhosis, hepatitis, hemolytic anemia, uveitis, Grave's disease, pernicious anemia, thrombocytopenia, Hashimoto's thyroiditis,

ATTORNEY DOCKET NO. 21085.0072U1

oophoritis, orchitis, adrenal gland diseases, anti-phospholipid syndrome, Wegener's granulomatosis, Behcet's disease, polymyositis, dermatomyositis, multiple sclerosis, vitiligo, ankylosing spondylitis, Pemphigus vulgaris, psoriasis, dermatitis herpetiformis, Addison's disease, Goodpasture's syndrome, Basedow's disease, thrombopenia purpura, allergy; and cardiomyopathy.

5 "Infection" or "infectious process" is defined as one organism being invaded by any type of foreign material or another organism. The results of an infection can include growth of the foreign organism, the production of toxins, and damage to the host organism. Infection includes viral, bacterial, parasitic, and fungal infections, for
10 example.

"Liver toxicity" is defined as an abnormal accumulation of toxic substances in the liver. A number of criteria can be used to assess the clinical significance of toxicity data: (a) type/severity of injury, (b) reversibility, (c) mechanism of toxicity, (d) interspecies differences, (e) availability of sensitive biomarkers of toxicity, (e) safety
15 margin (non toxic dose/pharmacologically active dose), and (f) therapeutic potential.

"Cancer therapy" is defined as any treatment or therapy useful in preventing, treating, or ameliorating the symptoms associated with cancer. Cancer therapy can include, but is not limited to, apoptosis induction, radiation therapy, and chemotherapy.

"Transplant" is defined as the transplantation of an organ or body part from one
20 organism to another.

"Transplant rejection" is defined as an immune response triggered by the presence of foreign blood or tissue in the body of a subject. In one example of transplant rejection, antibodies are formed against foreign antigens on the transplanted material.

As used throughout, by a "subject" is meant an individual. Thus, the "subject"
25 can include domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.) and birds. Preferably, the subject is a mammal such as a primate, and, more preferably, a human.

The terms “control levels” or “control cells” are defined as the standard by which a change is measured, for example, the controls are not subjected to the experiment, but are instead subjected to a defined set of parameters, or the controls are based on pre- or post-treatment levels.

5

GSK-3 and the Inflammatory Response

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase that was originally identified as a regulator of glycogen synthase, a key enzyme in glycogen metabolism. GSK-3 is involved in the regulation of a diverse array of cellular functions, including protein synthesis, cell proliferation, cell differentiation, microtubule assembly/disassembly, and apoptosis. GSK-3’s substrate specificity is unique in that phosphorylation of substrate only occurs if a phosphoserine or phosphotyrosine is present four residues C-terminal to the site of GSK phosphorylation.

There exist two isoforms of GSK-3, GSK-3 α and GSK-3 β , and they are strictly regulated via phosphorylation. Phosphorylation of GSK-3 β on Ser⁹ (Ser²¹ in GSK-3 α) by protein kinase B (PKB) causes its inactivation and this phosphorylation is the primary mechanism responsible for growth factor inhibition of this kinase. Activation of GSK3- β is dependent upon the phosphorylation of Tyr²¹⁶ (Tyr²⁷⁹ in GSK-3 α). Upon activation, GSK-3 phosphorylates a number of different cellular proteins, including p53, c-Myc, c-Jun, heat shock factor-1 (HSF-1), nuclear factor of activated T-cells, and cyclin D1. GSK-3 also has been shown to phosphorylate aberrant sites on the microtubule associated protein tau, which is critical for the progression of Alzheimer’s disease.

Endotoxin (also known as lipopolysaccharide, or LPS) is a key initiator of the early pro-inflammatory cascade that can mediate host tissue injury and lethal shock. Recognition of conserved microbial products, such as LPS, by the innate immune system leads to a variety of signal transduction pathways. These signal transduction pathways mediate the induction and secretion of cytokines that can regulate the level and duration of an inflammatory response. The systemic inflammatory response that

accompanies endotoxic shock is controlled by the levels of pro- and anti-inflammatory cytokines. In this regard, the ability to suppress pro-inflammatory cytokines and/or enhance anti-inflammatory cytokines, i.e. IL-10, reduces the toxic effects of LPS (Berg, 1995; Howard, 1993).

5 Cytokines are proteins made by cells that affect the behavior of other cells. Cytokines made by lymphocytes are often called lymphokines or interleukins (IL). Cytokines act on specific cytokine receptors on the cells they affect. Binding of the receptor induces activity in the cell such as growth, differentiation, or death. Several cytokines play key roles in mediating acute inflammatory reactions, namely IL-1, TNF-
10 a, IL-6, IL-11, IL-8 and other chemokines, GCSF, and GM-CSF. Of these, IL-1 (α and β) and TNF are extremely potent inflammatory molecules: they are the primary cytokines that mediate acute inflammation induced in animals by intradermal injection of bacterial lipopolysaccharide and two of the primary mediators of septic shock.

 Chronic inflammation may develop following acute inflammation and may last
15 for weeks or months, and in some instances for years. During this phase of inflammation, cytokine interactions result in monocyte chemotaxis to the site of inflammation where macrophage activating factors (MAF), such as IFN-g, MCP-1, and other molecules then activate the macrophages while migration inhibition factors (MIF), such as GM-CSF and IFN-g, retain them at the inflammatory site. The macrophages
20 contribute to the inflammatory process by chronically elaborating low levels of IL-1 and TNF which are responsible for some of the resulting clinical symptoms such as anorexia, cachexia, fever, sleepiness, and leukocytosis. The cytokines known to mediate chronic inflammatory processes can be divided into those participating in humoral inflammation, such as IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-13, and transforming
25 growth factor- β (TGF- β), and those contributing to cellular inflammation such as IL-1, IL-2, IL-3, IL-4, IL-7, IL-9, IL-10, IL-12, interferons (IFNs), IFN-g inducing factor (IGIF), TGF- β and TNF- α and - β (Feghali et al. *Frontiers in Bioscience* 2, d12-26, January 1, 1997).

The production of pro-inflammatory cytokines by cells of the innate immune system play an important role in mediating the initial host defense against invading pathogens. Furthermore, the inability to regulate the nature or duration of the host's inflammatory response can often mediate detrimental host effects as observed in
5 chronic inflammatory diseases. For example, in the early stages of sepsis, the host's inflammatory response is believed to be in a hyperactive state with a predominant increase in the production of pro-inflammatory cytokines that mediate host tissue injury and lethal shock. Thus, the ability of the innate immune system to dictate the levels of pro- and anti-inflammatory cytokine production is critical in limiting or
10 modulating the nature of the host inflammatory response.

Toll-like receptors (TLRs) are type I transmembrane proteins involved in innate immunity by recognizing microbial conserved structures. The ability to recognize these microbial structures results in the production of inflammatory mediators that dictate the magnitude and severity of inflammation. In this regard, sepsis as well as many
15 chronic inflammatory diseases are mediated by an inability to control the inflammatory response.

Upon TLR2-, TLR4-, TLR5-, or TLR9-stimulation, inhibition of GSK-3 resulted in the enhanced production of the anti-inflammatory cytokine, IL-10, by 3 to 6-fold, whereas the levels of pro-inflammatory cytokines including IL-1 β , IL-6, IL-12,
20 and IFN- γ were potently reduced by 60 to 90% (Examples 3 and 4). *In vivo* administration of the GSK-3 inhibitor SB216763 in mice resulted in a severe attenuation of endotoxin lethality when used in either a prophylactic or therapeutic manner. Moreover, analysis of *in vivo* cytokine production in these mice demonstrated that inhibition of GSK-3 resulted in a profound decrease in the systemic
25 levels of IL-1 β , IL-12, and IFN- γ , whereas the levels of IL-10 were increased by more than 2-fold when compared to LPS-treated controls. These findings demonstrate a central role for GSK-3 in differentially controlling the levels of pro- and anti-

inflammatory cytokine production upon TLR-stimulation and identify a potential therapeutic target that could serve to modulate the inflammatory response.

Methods of Treatment

5 An agent that inhibits GSK-3 activity or inhibits phosphorylation of GSK-3 can act in a number of different ways. For example, the agent can mediate phosphorylation of GSK-3 at either the ninth residue of glycogen synthase kinase 3 (ser⁹) or the twenty-first residue (ser²¹). One example of mediating phosphorylation of GSK-3 is to down-regulate the phosphorylation of GSK-3. Activated Akt is a key
10 physiological mediator of the PI3K pathway due to its ability to subsequently phosphorylate downstream targets, including the phosphorylation and subsequent inhibition of GSK-3 at position ser²¹ (GSK-3 α) and ser⁹ (GSK-3 β). Human monocytes stimulated with *E. coli* LPS exhibited ser⁹ phosphorylation at multiple time points in which the PI3K inhibitor LY294002 abolished the activity of *E. coli* LPS to
15 phosphorylate GSK-3.

 The agent can also inhibit activity of GSK-3. Phosphorylation on serine 9 or serine 21 can inhibit GSK-3 activity. Reducing phosphorylation of Tyrosine 216 or Tyrosine 279 can also inhibit GSK-3 activity.

Inflammation

20 Disclosed herein are methods of reducing the severity of inflammation in a subject. These methods include the steps of selecting a subject with inflammation or at risk for inflammation, and administering to the subject an effective amount of an agent that inhibits GSK-3 activity. Specifically, the agent can mediate phosphorylation of GSK-3 on the serine nine residue (GSK-3 β) or the serine twenty first residue (GSK-3 α).
25 Inhibition of GSK-3 activity or the phosphorylation of GSK-3 (Ser⁹ or Ser²¹) reduces the severity of inflammation in the subject.

 Inflammation can be associated with a number of different diseases and disorders. Examples of inflammation include, but are not limited to, inflammation

associated with hepatitis, inflammation associated with the lungs, and inflammation associated with an infectious process. Inflammation can also be associated with liver toxicity, which can be associated in turn with cancer therapy, such as apoptosis induction or chemotherapy, or a combination of the two, for example.

5 The inflammation can be associated with an inflammatory disease, as disclosed above.

 The inflammation can also be associated with cancer. Examples of types of cancer include, but are not limited to, lymphoma (Hodgkins and non-Hodgkins) B-cell lymphoma, T-cell lymphoma, leukemia such as myeloid leukemia and other types of
10 leukemia, mycosis fungoide, carcinoma, adenocarcinoma, sarcoma, glioma, blastoma, neuroblastoma, plasmacytoma, histiocytoma, melanoma, adenoma, hypoxic tumour, myeloma, AIDS-related lymphoma or AIDS-related sarcoma, metastatic cancer, bladder cancer, brain cancer, nervous system cancer, squamous cell carcinoma of the head and neck, neuroblastoma, glioblastoma, ovarian cancer, skin cancer, liver cancer, squamous
15 cell carcinomas of the mouth, throat, larynx, and lung, colon cancer, cervical cancer, breast cancer, cervical carcinoma, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, hematopoietic cancer, testicular cancer, colo-rectal cancer, prostatic cancer, and pancreatic cancer.

 Activated cells can also be treated at the site of inflammation.

20 "Activated cells" are defined as cells that participate in the inflammatory response. Examples of such cells include, but are not limited to, T-cells and B-cells , macrophages, NK cells, mast cells, eosinophils, neutrophils, Kupffer cells, antigen presenting cells, as well as vascular endothelial cells.

Infection

25 Inflammation can be caused by an infectious process in a subject. When the inflammation is associated with an infectious process, the infectious process can be associated with a viral infection. Examples of viral infections include, but are not limited to, Herpes simplex virus type-1, Herpes simplex virus type-2, Cytomegalovirus,

ATTORNEY DOCKET NO. 21085.0072U1

Epstein-Barr virus, Varicella-zoster virus, Human herpesvirus 6, Human herpesvirus 7, Human herpesvirus 8, Variola virus, Vesicular stomatitis virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Rhinovirus, Coronavirus, Influenza virus A, Influenza virus B, Measles virus, Polyomavirus, Human
5 Papillomavirus, Respiratory syncytial virus, Adenovirus, Coxsackie virus, Dengue virus, Mumps virus, Poliovirus, Rabies virus, Rous sarcoma virus, Yellow fever virus, Ebola virus, Marburg virus, Lassa fever virus, Eastern Equine Encephalitis virus, Japanese Encephalitis virus, St. Louis Encephalitis virus, Murray Valley fever virus, West Nile virus, Rift Valley fever virus, Rotavirus A, Rotavirus B, Rotavirus C, Sindbis virus,
10 Simian Immunodeficiency virus, Human T-cell Leukemia virus type-1, Hantavirus, Rubella virus, Simian Immunodeficiency virus, Human Immunodeficiency virus type-1, and Human Immunodeficiency virus type-2.

When the inflammation is associated with an infectious process, the infectious process can be associated with a bacterial infection. The bacterial infection can be
15 caused by either gram positive or gram negative bacterium.. The gram positive bacterium can be selected from the group consisting of: *M. tuberculosis*, *M. bovis*, *M. typhimurium*, *M. bovis* strain BCG, BCG substrains, *M. avium*, *M. intracellulare*, *M. africanum*, *M. kansasii*, *M. marinum*, *M. ulcerans*, *M. avium* subspecies *paratuberculosis*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus equi*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Listeria monocytogenes*,
20 *Listeria ivanovii*, *Bacillus anthracis*, *B. subtilis*, *Nocardia asteroides*, and other *Nocardia* species, *Streptococcus viridans* group, *Peptococcus* species, *Peptostreptococcus* species, *Actinomyces israelii* and other *Actinomyces* species, and *Propionibacterium acnes*.

25 The gram negative bacterium can be selected from the group consisting of: *Clostridium tetani*, *Clostridium perfringens*, *Clostridium botulinum*, other *Clostridium* species, *Pseudomonas aeruginosa*, other *Pseudomonas* species, *Campylobacter* species, *Vibrio cholerae*, *Ehrlichia* species, *Actinobacillus pleuropneumoniae*, *Pasteurella*

ATTORNEY DOCKET NO. 21085.0072U1

haemolytica, *Pasteurella multocida*, other *Pasteurella* species, *Legionella pneumophila*, other *Legionella* species, *Salmonella typhi*, other *Salmonella* species, *Shigella* species *Brucella abortus*, other *Brucella* species, *Chlamydi trachomatis*, *Chlamydia psittaci*, *Coxiella burnetti*, *Escherichia coli*, *Neisseria meningitidis*, *Neisseria gonorrhea*,
5 *Haemophilus influenzae*, *Haemophilus ducreyi*, other *Hemophilus* species, *Yersinia pestis*, *Yersinia enterocolitica*, other *Yersinia* species, *Escherichia coli*, *E. hirae* and other *Escherichia* species, as well as other *Enterobacteriaceae*, *Brucella abortus* and other *Brucella* species, *Burkholderia cepacia*, *Burkholderia pseudomallei*, *Francisella tularensis*, *Bacteroides fragilis*, *Fusobacterium nucleatum*, *Provetella* species and
10 *Cowdria ruminantium*.

The above examples of gram positive and gram negative bacteria are not intended to be limiting, but are intended to be representative of a larger population including all gram positive and gram negative bacteria, as well as non-gram test responsive bacteria. Examples of other species of bacteria include, but are not limited
15 to, *Abiotrophia*, *Achromobacter*, *Acidaminococcus*, *Acidovorax*, *Acinetobacter*, *Actinobacillus*, *Actinobaculum*, *Actinomadura*, *Actinomyces*, *Aerococcus*, *Aeromonas*, *Afiopia*, *Agrobacterium*, *Alcaligenes*, *Alloiococcus*, *Alteromonas*, *Amycolata*, *Amycolatopsis*, *Anaerobospirillum*, *Anaerorhabdus*, *Arachnia*, *Arcanobacterium*, *Arcobacter*, *Arthrobacter*, *Atopobium*, *Aureobacterium*,
20 *Bacteroides*, *Balneatrix*, *Bartonella*, *Bergeyella*, *Bifidobacterium*, *Bilophila*, *Branhamella*, *Borrelia*, *Bordetella*, *Brachyspira*, *Brevibacillus*, *Brevibacterium*, *Brevundimonas*, *Brucella*, *Burkholderia*, *Buttiauxella*, *Butyrivibrio*, *Calymmatobacterium*, *Campylobacter*, *Capnocytophaga*, *Cardiobacterium*, *Catonella*, *Cedecea*, *Cellulomonas*, *Centipeda*, *Chlamydia*, *Chlamydophila*,
25 *Chromobacterium*, *Chyseobacterium*, *Chryseomonas*, *Citrobacter*, *Clostridium*, *Collinsella*, *Comamonas*, *Corynebacterium*, *Coxiella*, *Cryptobacterium*, *Delftia*, *Dermabacter*, *Dermatophilus*, *Desulfomonas*, *Desulfovibrio*, *Dialister*, *Dichelobacter*, *Dolosicoccus*, *Dolosigranulum*, *Edwardsiella*, *Eggerthella*, *Ehrlichia*,

ATTORNEY DOCKET NO. 21085.0072U1

- Eikenella, Empedobacter, Enterobacter, Enterococcus, Erwinia, Erysipelothrix, Escherichia, Eubacterium, Ewingella, Exiguobacterium, Facklamia, Filifactor, Flavimonas, Flavobacterium, Francisella, Fusobacterium, Gardnerella, Gemella, Globicatella, Gordona, Haemophilus, Hafnia, Helicobacter, Helococcus, Holdemania*
- 5 *Ignavigranum, Johnsonella, Kingella, Klebsiella, Kocuria, Koserella, Kurthia, Kytococcus, Lactobacillus, Lactococcus, Lautropia, Leclercia, Legionella, Leminorella, Leptospira, Leptotrichia, Leuconostoc, Listeria, Listonella, Megasphaera, Methylobacterium, Microbacterium, Micrococcus, Mitsuokella, Mobiluncus, Moellerella, Moraxella, Morganella, Mycobacterium, Mycoplasma,*
- 10 *Myroides, Neisseria, Nocardia, Nocardiosis, Ochrobactrum, Oeskovia, Oligella, Orientia, Paenibacillus, Pantoea, Parachlamydia, Pasteurella, Pediococcus, Peptococcus, Peptostreptococcus, Photobacterium, Photorhabdus, Plesiomonas, Porphyrimonas, Prevotella, Propionibacterium, Proteus, Providencia, Pseudomonas, Pseudonocardia, Pseudoramibacter, Psychrobacter, Rahnella, Ralstonia,*
- 15 *Rhodococcus, Rickettsia Rochalimaea, Roseomonas, Rothia, Ruminococcus, Salmonella, Selenomonas, Serpulina, Serratia, Shewenella, Shigella, Simkania, Slackia, Sphingobacterium, Sphingomonas, Spirillum, Staphylococcus, Stenotrophomonas, Stomatococcus, Streptobacillus, Streptococcus, Streptomyces, Succinivibrio, Sutterella, Suttonella, Tatumella, Tissierella, Trabulsiella,*
- 20 *Treponema, Tropheryma, Tsakamurella, Turicella, Ureaplasma, Vagococcus, Veillonella, Vibrio, Weeksella, Wolinella, Xanthomonas, Xenorhabdus, Yersinia, and Yokenella.*

- When the inflammation is associated with an infectious process, the infectious process can be associated with a parasitic infection. Examples of parasitic infections
- 25 include, but are not limited to, *Toxoplasma gondii*, *Plasmodium* species such as *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*, and other *Plasmodium* species, *Trypanosoma brucei*, *Trypanosoma cruzi*, *Leishmania* species

ATTORNEY DOCKET NO. 21085.0072U1

such as *Leishmania major*, *Schistosoma* such as *Schistosoma mansoni* and other *Shistosoma* species, and *Entamoeba histolytica*.

When the inflammation is associated with an infectious process, the infectious process can be associated with a fungal infection. Examples of fungal infections
5 include, but are not limited to, *Candida albicans*, *Cryptococcus neoformans*,
Histoplasma capsulatum, *Aspergillus fumigatus*, *Coccidioides immitis*, *Paracoccidioides brasiliensis*, *Blastomyces dermatidis*, *Pneomocystis carinii*, *Penicillium marneffi*, and *Alternaria alternata*.

Furthermore, the infection can be associated with sepsis. Sepsis, also known as
10 systemic inflammatory response syndrome (SIRS), is a severe illness caused by
overwhelming infection of the bloodstream by toxin-producing bacteria. Sepsis occurs in
2 of every 100 hospital admissions. It is caused by bacterial infection that can originate
anywhere in the body. Common sites include, but are not limited to, the kidneys (upper
urinary tract infection), the liver or the gall bladder, the bowel (usually seen with
15 peritonitis), the skin (cellulitis), and the lungs (bacterial pneumonia).

Meningitis may also be accompanied by sepsis. In children, sepsis may
accompany infection of the bone (osteomyelitis). In hospitalized patients, common sites
of infection include intravenous lines, surgical wounds, surgical drains, and sites of skin
breakdown known as decubitus ulcers or bedsores. The infection is often confirmed by a
20 positive blood culture, though blood cultures may be negative in individuals who have
been receiving antibiotics. In sepsis, blood pressure drops, resulting in shock. Major
organs and systems, including the kidneys, liver, lungs, and central nervous system, stop
functioning normally. Sepsis is often life-threatening, especially in people with a
weakened immune system or other medical illnesses.

25 *Biological weapons*

Disclosed herein are methods of reducing the severity of inflammation or
infection in a subject prior to or after contact with an infectious agent such as a

ATTORNEY DOCKET NO. 21085.0072U1

biological weapon. Biological warfare agents include, but are not limited to, bacteria, fungi, and viruses.

Examples of bacteria that can be used in biological warfare include *Bacillus anthracis* (Anthrax), *Chlamydia psittaci* (Ornithosis), *Rickettsia prowasecki* (typhus),
5 *Vibrio cholerae* (Cholera) *Bartonella quintana* (Trench Fever) *Clostridium botulinum* (Botulism), *Rickettsia rickettsii* (Rocky Mountain Spotted Fever), *Yersinia pestis* (Plague), *Brucella melitensis* (Brucellosis), *Coxiella burnetti* (Q fever), *Rickettsia tsutsugamushii* (Scrub typhus), *Burkholderia mallei* (Glanders), *Francisella tularensis* (Tularemia), *Salmonella typhi* (Typhoid), *Burkholderia pseudomallei* (Meliodosis),
10 *Rickettsia moonseri* (Typhus), and *Shigella dysenteriae* (Dysentery).

Examples of fungi that can be used as biological warfare agents include, but are not limited to, *Coccidioides immitis* and *Histoplasma capsulatum*.

Examples of viruses that can be used as biological warfare agents include, but are not limited to, viral encephalitis agents, viral hemorrhagic fever agents,
15 Chikungunya virus, Hantaan virus, Marburg virus, Tick-borne encephalitis virus, Congo-Crimean haemorrhagic fever virus, Japanese encephalitis virus, Monkey pox virus, Variola virus, Dengue fever virus, Junin virus, Omsk hemorrhagic fever virus, Venezuelan equine encephalitis virus, Eastern equine encephalitis virus, Lassa fever virus, Rift valley fever virus, Western equine encephalitis virus, Ebola virus,
20 Lymphocytic choriomeningitis virus, Russian Spring-Summer encephalitis virus, White pox, Equine morbillivirus, Machupo virus, Smallpox virus, and Yellow fever virus.

The agents disclosed herein can be administered to a subject at risk of exposure to a biological warfare agent. For example, the agent can be administered to military troops or those at high risk of exposure to a biological warfare agent. The agent can then
25 prevent or reduce the severity of infection or inflammation in a subject. The agents disclosed herein can be administered to a subject less than 1, 2, 3, 4, 5, 6, 12, 24, 36, or 48 hours, or more, prior to exposure. The agent can also be administered to a subject after the subject has been exposed to a biological warfare weapon. The agents can also

ATTORNEY DOCKET NO. 21085.0072U1

be administered to the subject less than 1, 2, 3, 4, 5, 6, 12, 24, 36, or 48 hours, or more, after exposure. When the subject has been exposed prior to treatment, the subject should be treated as quickly as possible after exposure. The agents disclosed herein can be administered in a variety of ways, as disclosed

5 *Biological Systems*

Disclosed are methods of reducing the severity of inflammation in a biological system. These methods can include the steps of selecting an inflamed biological system, or a biological system at risk for inflammation, and administering to the biological system an effective amount of an agent that inhibits GSK-3 or mediates the
10 phosphorylation of GSK-3, inhibition or mediation of phosphorylation of GSK-3 reducing the severity of inflammation in the biological system.

The biological system can comprise an *in vitro* or *ex vivo* culture system. If the system comprises an *in vitro* culture, the culture can be used for screening, for diagnostic purposes, or for the preservation of biological materials. If an *in vitro* culture
15 system is used, the disclosed compositions can be delivered to any type of cell. For example, they can be delivered to any type of mammalian cell. Exemplary types of cells neuron, glia, fibroblast, chondrocyte, osteocyte, endothelial, and hepatocyte.

Biological preservation of organs, tissues and cells are employed in many clinical and veterinary applications wherein living material, is harvested and stored *in*
20 *vitro* for some period of time before use. Examples of such applications include organ storage and transplants, autologous and allogeneic bone marrow transplants, whole blood transplants, platelet transplants, cord blood and other stem cell transplants, embryo transfer, artificial insemination, *in vitro* fertilization, skin grafting and storage of tissue biopsies for diagnostic purposes. Preservation techniques are also important in the
25 storage of cell lines for experimental use in hospital, industrial, university and other research laboratories.

If *ex vivo* methods are employed, cells or tissues can be removed and maintained outside the body according to standard protocols well known in the art. The biological system can comprise a tissue culture system or an organ culture system.

5 The agents described herein can be introduced into the cells via any gene transfer mechanism, such as, for example, calcium phosphate mediated gene delivery, electroporation, microinjection or proteoliposomes. The transduced cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or homotopically transplanted back into the subject per standard methods for the cell or tissue type.

Surgery and Transplantation

10 Disclosed herein are methods of reducing the severity of inflammation in a subject prior to or after surgery. Inflammation associated with surgery can be caused by an infection, for example. Infections associated with surgery are common, particularly during invasive procedures and those requiring implants, such as joint replacement surgery. Because the immune system is unable to attack bacteria that live on implants, 15 infections can be a serious problem. If an infection of an implant goes untreated, the problem can worsen, and the bacteria can gain such a foothold that can become a systemic problem.

The agents disclosed herein can be administered to a subject less than 1, 2, 3, 4, 5, 6, 12, 24, 36, or 48 hours, or more, prior to surgery. The agents can also be 20 administered to the subject less than 1, 2, 3, 4, 5, 6, 12, 24, 36, or 48 hours, or more, after surgery. The agent can be administered to the subject in a variety of ways, as disclosed herein.

Disclosed are methods of reducing the risk of inflammation in a recipient of an implantation or a transplantation. These methods can include the steps of contacting the 25 implant or transplant with an agent that inhibits GSK-3 activity or mediates the phosphorylation of GSK-3 (ser⁹ or ser²¹), inhibition of GSK-3 activity or mediation of phosphorylation of GSK-3 reducing the risk of inflammation of the recipient.

ATTORNEY DOCKET NO. 21085.0072U1

Inflammation can be associated with transplant rejection in a transplant or implant recipient. As disclosed above, “transplant rejection” is defined as an immune response triggered by the presence of foreign blood or tissue in the body of a subject. In one example of transplant rejection, antibodies are formed against foreign antigens on
5 the transplanted material. The transplantation can be, for example, tissue, cell or organ transplantation, such as liver, kidney, skin, corneal, pancreas, pancreatic islet cells, eyes, heart, or any other transplantable organ of the body.

Transplantation immunology refers to an extensive sequence of events that occurs after an allograft or a xenograft is removed from a donor and then transplanted
10 into a recipient. Tissue is damaged at both the graft and the transplantation sites. An inflammatory reaction follows immediately, as does activation of biochemical cascades. Such as inflammatory reaction can be reduced using the methods taught herein. In the inflammatory reaction, a series of specific and nonspecific cellular responses ensues as antigens are recognized. Antigen-independent causes of tissue damage (i.e., ischemia,
15 hypothermia, reperfusion injury) are the result of mechanical trauma as well as disruption of the blood supply as the graft is harvested. In contrast, antigen-dependent causes of tissue damage involve immune-mediated damage.

Macrophages release cytokines (e.g., tumor necrosis factor, interleukin-1), which heighten the intensity of inflammation by stimulating inflammatory endothelial
20 responses; these endothelial changes help recruit large numbers of T cells to the transplantation site.

Damaged tissues release pro-inflammatory mediators (e.g., Hageman factor (factor XII) that trigger several biochemical cascades. The clotting cascade induces fibrin and several related fibrinopeptides, which promote local vascular permeability and
25 attract neutrophils and macrophages. The kinin cascade principally produces bradykinin, which promotes vasodilation, smooth muscle contraction, and increased vascular permeability.

ATTORNEY DOCKET NO. 21085.0072U1

Rejection is the consequence of the recipient's alloimmune response to the nonself antigens expressed by donor tissues. In hyperacute rejection, transplant subjects are serologically presensitized to alloantigens (i.e., graft antigens are recognized as nonself). Histologically, numerous polymorphonuclear leukocytes (PMNs) exist within the graft vasculature and are associated with widespread microthrombin formation and platelet accumulation. Little or no leukocyte infiltration occurs. Hyperacute rejection manifests within minutes to hours of graft implantation. Hyperacute rejection has become relatively rare since the introduction of routine pretransplantation screening of graft recipients for antidonor antibodies.

10 In acute rejection, graft antigens are recognized by T cells; the resulting cytokine release eventually leads to tissue distortion, vascular insufficiency, and cell destruction. Histologically, leukocytes are present, dominated by equivalent numbers of macrophages and T cells within the interstitium. These processes can occur within 24 hours of transplantation and occur over a period of days to weeks.

15 In chronic rejection, pathologic tissue remodeling results from peritransplant and posttransplant trauma. Cytokines and tissue growth factor induce smooth muscle cells to proliferate, to migrate, and to produce new matrix material. Interstitial fibroblasts are also induced to produce collagen. Histologically, progressive neointimal formation occurs within large and medium arteries and, to a lesser extent, within veins of the graft. Leukocyte infiltration usually is mild or even absent. All these result in reduced blood flow, with subsequent regional tissue ischemia, fibrosis, and cell death. (Prescilla et al. <http://www.emedicine.com>, Immunology of Transplant Rejection, updated June 20, 2003).

25 Transplant rejection may occur within 1-10 minutes of transplantation, or within 10 minutes to 1 hour of transplantation, or within 1 hour to 10 hours of transplantation, or within 10 hours to 24 hours of transplantation, within 24 hours to 48 hours of transplantation, within 48 hours to 1 month of transplantation, within 1 month to 1 year

of transplantation, within 1 year to 5 years of transplantation, or even longer after transplantation.

The implant or transplant can be contacted with an agent that mediates phosphorylation or inhibits activity of GSK-3 prior to or during implantation or
5 transplantation into the recipient. The implant or transplant can be contacted at least 1, 5, 10, 15, 20, 30, 45, or 60 minutes prior to implantation or transplantation. The implant or transplant can also be contacted at least 2, 3, 4, 5, 10, 12, 24, 36, or 48 hours prior to implantation or transplantation.

The implant or transplant can also be contacted with an agent that mediates
10 phosphorylation or inhibits activity of GSK-3 after implantation or transplantation into the recipient. The implant or transplant can be contacted at least 1, 5, 10, 15, 20, 30, 45, or 60 minutes after implantation or transplantation. The implant or transplant can also be contacted at least 2, 3, 4, 5, 10, 12, 24, 36, or 48 hours after implantation or transplantation.

15 **Compositions and Screening Methods**

Disclosed are GSK-3 peptides and nucleic acids that can be used with the methods disclosed throughout the application. Also disclosed are the agents that modulate GSK-3 to be used within the methods disclosed herein, as well as screening methods that allow for identification of these agents. These and other materials are
20 disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of
25 modifications that can be made to a number of molecules including the amino acids are discussed, specifically contemplated is each and every combination and permutation of the transgene and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of

ATTORNEY DOCKET NO. 21085.0072U1

molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed.

5 Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments
10 of the disclosed methods.

GSK-3

As discussed above, GSK-3 is a ubiquitously expressed, highly conserved serine/threonine protein kinase that is involved in the signal transduction cascades of multiple cellular processes. There exist two isoforms of GSK-3, GSK-3 α (SEQ ID NO:
15 1) and GSK-3 β (SEQ ID NO: 2), and they are strictly regulated via phosphorylation. The nucleic acids of GSK-3 α and GSK-3 β are represented by SEQ ID NO: 3 and SEQ ID NO: 4, respectfully. Phosphorylation of GSK-3 β on Ser⁹ (Ser²¹ in GSK-3 α) by protein kinase B (PKB) causes its inactivation is the primary mechanism responsible for growth factor inhibition of this kinase. Activation of GSK3- β is dependent upon the
20 phosphorylation of Tyr²¹⁶ (Tyr²⁷⁹ in GSK-3 α).

SEQ ID NO: 1 (GSK-3 α peptide sequence)

mshgggpgsggg pggsggrats sfaepggggg gggggpggsa sgpggtgggk asvgamgggv
gasssgggpg gsgggsggpg gagtsfpppg vklgrdsgkv ttvvtlgqg persqevayt
25 dikvigngsf gvvyqarlar trelvaikkv lqdkrfknre lqimrkldhc nivrlryffy
ssgekkdely lnlvleyvpe tvyrvarhft kakltipily vkvmyqlfr slayihsqgv
chrdikpqnl lvdptavlk lcdfgsakql vrgepnvsyi csryrapel ifgatdytss
idvwsagcvi aelllgqipf pgdsgvdqlv eiikvlgtpt requiremnpn ytefkfpqik

ATTORNEY DOCKET NO. 21085.0072U1

ahpwtkvfks rtppeaialc ssleytpss rlspleacah sffdelrclg tqlpnnrplp
plfnfsagel siqpslnail ipphlrspag ttltptssqa ltetptssdw qstdatpilt nss

SEQ ID NO: 2 (GSK-3 β peptide sequence)

5 msgrprttsf aesckpvqqp safgsmkvsr dkdgskvttv vatpgqgpdv pgevsvytdk
vigngsfgvv yqaklcsge lvaikkvlqd krkfnrelqi mrkl dhcniv rlyffysg
ekkdevylnl vldyvpetyv rvarhysrak qtlpviyvk ymyqlfrsla yihsfgichr
dikpqnlld pdtavklcd fgsakqlvrg epnvsvicsr yyrapelifg atdytssidv
wsagcvlael llgqipfpgd sgvdqlveii kvlgtpreq iremnpnyte fkfpqikahp
10 wtkvfrtrp peaialsrl leytparl pleacahsff delrdpnvkl pngrdtpalf
nftqelssn pplatilipp hariqaaasp panataasdt nagdrqtnn aasasasnt

SEQ ID NO: 3 (GSK-3 α nucleic acid sequence)

gcggcgcggc ctggaagagg ccaggggccc ggggaggcgg cggcagcggc ggcggctggg
15 gcagcccggg cagcccgagc cccgcagcct gggcctgtgc tcggcgccat gaggcgcggc
gggccttcgg gaggcgggcc tgggggctcg ggcaggggcg ggactagctc gtgcgggag
cccggcgggc gaggcgggagg aggcggcggc ggccccggag gctcggcctc cgccccaggc
ggcaccggcg gcggaaaggc atctgtcggg gccatgggtg ggggcgtcgg ggcctcgagc
tcggggggtg gaccggcggg cagcgggcga ggaggcagcg gaggccccgg cgcaggcact
20 agcttccgc cgccgggggt gaagctgggc cgtgacagcg ggaaggtgac cacagtcgta
gccactctag gccaaaggccc agagcgctcc caagaagtgg ctacacgga catcaaagt
attggcaatg gctcatttg ggtcgtgtac caggcacggc tggcagagac cagggaacta
gtcgccatca agaaggttct ccaggacaag aggttcaaga accgagagct gcagatcatg
cgtaagctgg accactgcaa tattgtgagg ctgagatact tttctactc cagtggcgag
25 aagaaagacg agctttacct aaatctggtg ctggaatatg tgcccagagc agtgatccgg
gtggccccgc acttcaccaa ggccaagttg accatcccta tcctctatgt caaggtgtac
atgtaccagc tcttcgcag cttggcctac atccactccc agggcgtgtg tcaccgcgac
atcaagcccc agaacctgct ggtggaccct gacactgctg tctcaagct ctgcgattt

ATTORNEY DOCKET NO. 21085.0072U1

ggcagtgcaa agcagttggt ccgaggggag cccaatgtct cctacatctg ttctcgctac
taccggggccc cagagctcat ctttgagacc actgattaca cctcatccat cgatgtttgg
tcagctggct gtgtactggc agagctcttc ttgggccagc ccatcttccc tggggacagt
ggggtggacc agctgggtgga gatcatcaag gtgctgggaa caccaacccg ggaacaaatc
5 cgagagatga accccaacta cacggagttc aagttccctc agattaaagc tcacccttg
acaaagggtg tcaaattctg aacgccgcca gagggcatcg cgctctgctc tagcctgctg
gagtacacc cactctcaag gctctcccca ctagaggcct gtgcgcacag cttctttgat
gaactgcgat gtctgggaac ccagctgcct aacaaccgcc cacttcccc tctctcaac
ttcagtgtg gtgaactctc catccaaccg tctctcaacg ccatttctcat cctctctac
10 ttgaggctcc cagcgggcac taccacctc acccgtctc cacaagcttt aactgagact
ccgaccagct cagactggca gtcgaccgat gccacaccta cctcactaa ctctctga
gggccccacc aagcaccctt ccacttccat ctgggagccc caagaggggc tgggaagggg
ggccatagcc catcaagctc ctgccctggc tggggcccta gactagaggg cagaggtaaa
tgagtccctg tccccacctc cagtccctcc ctcaccagcc tcaccctgt ggtgggcttt
15 ttaagaggat tttaactggt tgtggggagg gaagagaagg acagggtgtt ggggggatga
ggacctcta ccccttggc cccctccct ccccagacc tccacctct ccagaccccc
tccctctg tctccctgt aaatagaacc agcccagccc gtctctctt ccttccctg
gccccgggt gtaaatagat tgttataatt ttttcttaa agaaaacgtc gattcgacc
gtccaacctg gccccgccc tctacagct gtaactcccc tctgtctc tgccccaaag
20 gtctactccc tctcacccc accctggagg gccaggggag tggagagagc tctgatgtc
ttagttcca cagtaagggt tgctgtgtga cagacctccg ttaataaat tattggcatg
aaaacctgaa aaaaaaaaaa aaaaaaaaaa

SEQ ID NO: 4 (GSK-3 β nucleic acid)

25 atcatctata tgftaaatat ccgtgccgat ctgtcttgaa ggagaaatat atcgcttgtt
ttgttttta tagtatacaa aaggagtga aagccaagag gacgaagtct tttctttt
cttctgtggg agaacttaat gtgcattta tegttaacct aacaccccaa cataaagaca
aaaggaagaa aaggaggaag gaaggaaaag gtgattcgcg aagagagtga tcatgtcagg

ATTORNEY DOCKET NO. 21085.0072U1

gcggcccaga accacctcct ttgcggagag ctgcaagccg gtgcagcagc cttcagcttt
tggcagcatg aaagtttagca gagacaagga cggcagcaag gtgacaacag tgggtggcaac
tcctggggcag ggtccagaca ggccacaaga agtcagctat acagacacta aagtgttgg
aaatggatca tttggtgtgg tatatcaagc caaactttgt gattcaggag aactggtcgc
5 catcaagaaa gtattgcagg acaagagatt taagaatcga gagctccaga tcatgagaaa
gctagatcac tgtaacatag tccgattgcg ttatttcttc tactccagtg gtgagaagaa
agatgaggtc tatcttaac tggtgctgga ctatgttccg gaaacagtat acagagttgc
cagacactat agtcgagcca aacagacgct ccctgtgatt tatgtcaagt tgtatatgta
tcagctgttc cgaagttag cctatatcca ttccittgga atctgccatc gggatattaa
10 accgcagaac ctcttgttgg atctgatac tgcgttatta aaactctgtg actttggaag
tgcaaagcag ctggtccgag gagaacccaa tgttctgtat atctgttctc ggtactatag
ggcaccagag ttgatctttg gagccactga ttatacctct agtatagatg tatggtctgc
tggctgtgtg ttggctgagc tgttactagg acaaccaata ttccagggg atagtgggtg
ggatcagttg gtagaaataa tcaaggctct gggaactcca acaagggagc aaatcagaga
15 aatgaaccca aactacacag aatttaaatt cctcacaatt aaggcacatc cttggactaa
ggattcgtca ggaacaggac atttcacctc aggagtgcgg gtcttccgac cccgaactcc
accggaggca attgcactgt gtagccgtct gctggagtat acaccaactg cccgactaac
accactggaa gcttgtgcac attcattttt tgatgaatta cgggacccaa atgtcaaaact
accaaattggg cgagacacac ctgcactctt caacttcacc actcaagaac tgtcaagtaa
20 tccacctctg gctaccatcc ttattctccc tcatgctcgg attcaagcag ctgcttcaac
ccccacaaat gccacagcag cgtcagatgc taatactgga gaccgtggac agaccaataa
tgctgttctt gcatcagctt ccaactccac ctgaacagtc ccgagcagcc agctgcacag
gaaaaaccac cagttacttg agtgtcactc agcaacactg gtcacgtttg gaaagaatat
taaaaaaaaa aaaaaaaaaa

25

GSK-3 Modulating Agents

Agents useful with the methods disclosed herein include any agent that can inhibit the activity of GSK-3 or otherwise modulate the phosphorylation of GSK-3. An

ATTORNEY DOCKET NO. 21085.0072U1

example of agents that can inhibit the activity of GSK-3 or modulate the phosphorylation of GSK-3 includes lithium chloride and SB216763. Another example is Ro31-8220. Compounds related to GSK-3 and lithium chloride that are able to inhibit the activity of GSK-3 or modulate the phosphorylation of GSK-3 can also be used.

- 5 These agents can first be tested in a screening assay, for example. Other agents not related to lithium chloride and SB216763 can also be identified by screening methods.

Screening methods for identifying compounds are well known in the art, such as those found in U.S. Patent 6,441,053. An example of a screening method that can be used to identify an inhibitor or modulator of phosphorylation of GSK-3 comprises
10 providing a mixture comprising GSK-3, a source of phosphate, a GSK-3 substrate and a GSK-3 assay buffer, incubating the mixture in the presence or absence of a test compound, and measuring the level of phosphorylation of the GSK-3 substrate. A lower level of phosphorylation of the GSK-3 substrate in the presence of the test compound compared with the level of phosphorylation of the GSK-3 substrate in the absence of the
15 test compound is an indication that the test compound is a GSK-3 inhibitor. Such methods can be used in conjunction with high throughput screens. The GSK-3 inhibitor should also be assessed by detecting a reduction in inflammation or a marker thereof.

In the assay, GSK-3 may be provided as a protein or it may be provided in the assay mixture as an mRNA specifying GSK-3. When the assay comprises cell-free
20 components, GSK-3 is provided as the protein. When the assay is conducted in the milieu of a cell, GSK-3 may be provided as either the protein or as an mRNA specifying GSK-3, wherein, in order that GSK-3 be available in the assay, the mRNA is translated and GSK-3 protein is thereby produced. GSK-3 may also be provided by expression of a plasmid which encodes GSK-3. Standard molecular biology techniques may be used to
25 construct operable plasmids encoding GSK-3 and to express the plasmid in cells (Sambrook, et al., 1989, In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). Contacting a cell or subject comprising GSK-3, an agent that induces inflammation, and the agent to be tested, and reducing the level of

inflammation as compared to a control treated with the agent that induces inflammation indicates an agent that modulates GSK-3 and inflammation.

As discussed herein, the method of identifying a GSK-3 inhibitor can be performed either *in vitro* wherein the assay mixture is cell-free, *in vitro* wherein live
5 cells are included in the assay, or *in vivo* in an animal. Thus, in one aspect of the invention, the mixture is contained within a eukaryotic cell and the method of the invention may be performed wherein some of the components of the assay mixture may be provided exogenously to a cell by microinjection of the components therein, and some of the components may be endogenous in the cell.

10 When a eukaryotic cell is used, one or more of GSK-3, GSK-3 substrate and the test compound may be injected into the eukaryotic cell prior to the incubation. The cell so injected is then incubated under conditions which facilitate GSK-3 activity and the level of GSK-3 activity is subsequently measured following the incubation period using the assays described herein.

15 The eukaryotic cell which is useful in the methods of the invention may be any one of a *Xenopus laevis* oocyte, a *Xenopus laevis* embryo cell, a mammalian cell (such as a 10T1/2 cell), a *Drosophila melanogaster* S2 cell, a *Dictyostelium discoideum* cell and a yeast cell. The eukaryotic cell can be a *Xenopus laevis* embryo ventral vegetal blastomere cell.

20 The source of phosphate for use in the methods of the invention may be any common source of phosphate, including, but not limited to, a nucleotide triphosphates such as, but not limited to, ATP or GTP. The phosphate source can have bound thereon a detectable label which label is transferred with the phosphate group to the GSK-3 substrate during the reaction. In this manner, phosphorylated GSK-3 substrate may be
25 distinguished from non-phosphorylated GSK-3 substrate in that the phosphorylated substrate will contain the detectable label whereas the non-phosphorylated substrate will not contain the label. In another embodiment, the phosphate source does not have bound thereon a detectable label; instead, phosphorylated GSK-3 substrate may be

ATTORNEY DOCKET NO. 21085.0072U1

distinguished from non-phosphorylated GSK-3 substrate, for instance by recognition of one form of the substrate, but not the other, by an antibody.

The detectable label can include any known or heretofore unknown detectable label which is transferred to the GSK substrate upon transfer of a phosphate group thereto as a result of GSK-3 activity. Labels which are useful include, but are not limited to, radioactive labels and non-radioactive labels, such as biotin and the like.

The GSK-3 can be any eukaryotic GSK-3. The GSK-3 which is useful includes, but is not limited to, human GSK-3 α ., human GSK-3 β , *Xenopus laevis* GSK-3 α ., *Xenopus laevis* GSK-3 β , bacterially-expressed *Xenopus laevis* GSK-3 β , the expression product of the *Drosophila melanogaster* zw3/sgg gene, and the expression product of the *Dictyostelium discoideum* gskA gene.

The test agent used in the method of the invention may include bis-indolyl maleimides and structurally related compounds, staurosporine, derivatives thereof, and structurally-related compounds of a class known to inhibit other protein kinases, particularly those agents known to inhibit protein kinase C or GSK-3 indirectly.

One example of a method of screening a test compound includes using an *in vitro* or the *in vivo* assay wherein at least a pair of assay mixtures is provided. The test agent to be screened is added to one assay mixture in each pair, and is not added to the other assay mixture in the pair. GSK-3 activity is determined in each assay mixture of the pair. If the test agent inhibits GSK-3 or modulates its phosphorylation, then GSK-3 activity will be lower in the assay mixture which contains the test agent than in the assay mixture which does not contain the test compound. One skilled in the art will appreciate that it is desirable to screen test compounds using several different concentrations of the test compound in different assay pairs.

To screen a test compound *in vivo* in an animal, an animal having cells which express GSK-3 is selected. The test compound is administered to at least one animal, and at least one other animal is not administered the test compound. The activity of GSK-3 in each animal may be assessed in numerous ways, including observation of a

macroscopic trait which is influenced by the level of GSK-3 activity in the animal, analysis of the composition of a tissue sample, such as a blood sample, which composition is influenced by the level of GSK-3 activity in the animal, measurement of GSK-3 activity in a tissue sample of the animal, and others methods known to those of skill in the art.

The agent can follow the guidelines of "Lipinski's Rule of Five." (Lipinski, 1997). Lipinski's Rule of Five is particularly useful when the goals of compound design are (i) to have less than 5 hydrogen donors, (ii) less than 10 hydrogen bond acceptors, (iii) molecular weight of less than 500 Daltons and (iv) the log of the partition coefficient, P (where $P = \frac{\text{concentration of the compound in water}}{\text{concentration of the compound in 1 octanol}}$) is less than 5. The Lipinski Rule of Five is a useful guideline, however, the composition is not limited to these parameters.

A wide variety of small molecular weight compounds can be used in the screening methods disclosed herein. Such compounds include, but are not limited to, any compositions which are being tested for drug discovery or development. Such compounds include, but are not limited to, nucleic acids including functional nucleic acids, amino acids including peptides and proteins and fragments thereof, and various other chemical compounds. Compounds can be aqueous- or lipid-soluble. Compounds can be dissolved or suspended within solution, or affixed to a solid-support. Solid supports may include, but are not limited to, insoluble polymer beads or a polymeric matrix coated with one or a plurality of individual compounds, or with combinatorial chemistries. Dosages and volumes which are administered in the screening methods can be varied so as to optimize dosages for further studies or to rank compounds as to their toxicity and/or potency. Information resulting from variations in conditions can be used to prioritize chemicals for further study, to delineate the relative toxicities of structurally related chemicals, and/or to identify the proper dose range for subsequent toxicity studies (see e.g., Harris, et al., Fundam. Appl. Toxicol. 19:186-196).

ATTORNEY DOCKET NO. 21085.0072U1

The carbon-carbon backbone of the compounds can be saturated or unsaturated, cyclic or linear. These aforementioned compounds include, but are not limited to, carbohydrates, polyalcohols (e.g., ethylene glycol and glycerol) and polyphenols (e.g., hydroquinones and tetracyclines). Carbohydrate- and polysaccharide-transformed
5 compounds are defined herein so as to include all chemical moieties possessing a saccharide unit or which are transformed from a saccharide. These compounds can also include glycopeptides, glycolipids and other biopolymers (or biomacromolecules) containing saccharides, either in their entirety or as part of the molecular framework. The term carbohydrates merely represent a portion of a much larger family of
10 polyhydroxylated organic compounds. In addition, carbohydrated/polyhydroxylated organic compounds include, but are not limited to: monomeric acyclic compounds (e.g., ethylene glycol, glycerol and 1,2,3-trihydroxy pentane); polymeric acyclic compounds (e.g., di- or tri-ethylene diglycol; monomeric cyclic compounds (e.g., inositol and 1,2,3-trihydroxycyclopentane); polymeric cyclic compounds (e.g., di-inositol); polymeric and
15 monomeric unsaturated compounds (e.g., tetrahydroxy-1,4-quinone) and polyphenols (e.g., tetracyclines) and derivatives, analogs and fragments thereof.

With respect to the generation of small molecular weight compound libraries, the combination of biochemical diversity is often synergistic with the metabolic diversity obtained from the *in vivo* production of “natural products”. Collections of
20 starting compounds, for example peptides, can be administered to cultures of microorganisms. In accord, each microbial strain may potentially create numerous modified peptides or peptide byproducts, thus generating a “metabolite library”. Because each of these aforementioned cultures can contain a very complex mixture of metabolites, a highly efficacious method of screening is required (i.e., high throughput
25 screening). An aliquot of the library is incubated with each of the many strains typical of a microorganism fermentation screening program, and the media screened utilizing an HTS-based assay. Furthermore, natural product diversity can be screened by creating a mixture of combinatorially-tagged liposomes; wherein each liposome preferably

ATTORNEY DOCKET NO. 21085.0072U1

encapsulates only one member or a simple mixture of a natural product compound library. The libraries which are generated by the methodologies disclosed herein may be screened for GSK-3 modulating activity.

Administration

5 Disclosed are agents that can inhibit the activity of GSK-3 or modulate, i.e. down-regulate, the phosphorylation of GSK-3 on Tyr²¹⁶ (GSK-3 β) or on Tyr²⁷⁹ (GSK-3 α) or induce or enhance phosphorylation on ser⁹ (GSK-3 β) or ser²¹ (GSK-3 α). The agents can be administered *in vivo* in a pharmaceutically acceptable carrier. By “pharmaceutically acceptable” is meant a material that is not biologically or otherwise
10 undesirable, i.e., the material may be administered to a subject, along with a nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the
15 subject, as would be well known to one of skill in the art.

Delivery

 The disclosed agents can be delivered to the target cells in a variety of ways. For example, the agents can be delivered through electroporation, or through lipofection, or through calcium phosphate precipitation. The delivery mechanism chosen will depend
20 in part on the type of cell targeted and whether the delivery is occurring for example *in vivo* or *in vitro*.

 Thus, the agents can comprise, for example, lipids such as liposomes, such as cationic liposomes (e.g., DOTMA, DOPE, DC-cholesterol) or anionic liposomes. Liposomes can further comprise proteins to facilitate targeting a particular cell, if
25 desired. Administration of an composition comprising a compound and a cationic liposome can be administered to the blood afferent to a target organ or inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, see, e.g., Brigham et al. Am. J. Resp. Cell. Mol. Biol. 1:95-100 (1989); Felgner et al. Proc. Natl.

ATTORNEY DOCKET NO. 21085.0072U1

Acad. Sci *USA* 84:7413-7417 (1987); U.S. Pat. No.4,897,355. Furthermore, the compound can be administered as a component of a microcapsule that can be targeted to specific cell types, such as macrophages, or where the diffusion of the compound or delivery of the compound from the microcapsule is designed for a specific rate or dosage.

5 The agents of the present invention can also be administered using methods of delivering exogenous nucleic acids, such as in gene therapy. See, e.g., U.S. Patent No. 5,399,346, which is incorporated by reference herein in its entirety for the methods of delivery. Primary cells transfected with the gene for the agent of the present invention
10 can additionally be transfected with tissue specific promoters to target specific organs, tissue, grafts, or cells.

Administration of the agents disclosed herein can occur in conjunction with other therapeutic agents. Thus, the agents of the present invention can be administered alone or in combination with one or more therapeutic agents. For example, a subject
15 can be treated with the disclosed agent alone, or in combination with chemotherapeutic agents, antibodies, antivirals, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines, chemokines, and/or growth factors. Combinations may be administered either concomitantly (e.g., as an admixture), separately but simultaneously (e.g., via separate intravenous lines into the same subject),
20 or sequentially (e.g., one of the compounds or agents is given first followed by the second). Thus, the term "combination" or "combined" is used to refer to either concomitant, simultaneous, or sequential administration of two or more agents.

The agents disclosed herein are of benefit to subjects who are experiencing inflammation or are at risk for inflammation. Because the agents disclosed herein
25 reduce the activity of GSK-3, thereby reducing the severity or duration of the inflammation, any subject that can benefit from a reduction in the activity of GSK-3 can be administered the agents disclosed herein.

ATTORNEY DOCKET NO. 21085.0072U1

The compositions comprising an agent disclosed herein in a pharmaceutically acceptable carrier may be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, topically or the like, although topical intranasal administration or administration by inhalant is typically preferred. As used herein, "topical intranasal administration" means delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid or vector. The latter may be effective when a large number of animals is to be treated simultaneously. Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. The exact amount of the compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the disorder being treated, the particular nucleic acid or vector used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.

Parenteral administration of the composition, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein in its entirety for the methods taught.

The compositions may be in solution or in suspension (for example, incorporated into microparticles, liposomes, or cells). These compositions may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The

ATTORNEY DOCKET NO. 21085.0072U1

following references are examples of the use of this technology to target specific proteins to given tissue (Senter, et al., *Bioconjugate Chem.*, 2:447-451, (1991); Bagshawe, K.D., *Br. J. Cancer*, 60:275-281, (1989); Bagshawe, et al., *Br. J. Cancer*, 58:700-703, (1988); Senter, et al., *Bioconjugate Chem.*, 4:3-9, (1993); Battelli, et al., 5 *Cancer Immunol. Immunother.*, 35:421-425, (1992); Pietersz and McKenzie, *Immunolog. Reviews*, 129:57-80, (1992); and Roffler, et al., *Biochem. Pharmacol.*, 42:2062-2065, (1991)). Vehicles such as "stealth" and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor 10 targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are 15 degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and 20 ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, *DNA and Cell Biology* 10:6, 399-409 (1991)).

Pharmaceutically Acceptable Carriers

Delivery of the agents disclosed herein can be used therapeutically in 25 combination with a pharmaceutically acceptable carrier. Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions can be administered

ATTORNEY DOCKET NO. 21085.0072U1

intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.

Pharmaceutical compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.

- 5 Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like.

10 The pharmaceutical composition may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection. The disclosed compounds can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

- 15 Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

- 25 Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

ATTORNEY DOCKET NO. 21085.0072U1

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.

Some of the compositions may potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

Therapeutic Uses

The dosage ranges for the administration of the agents disclosed herein are those large enough to produce the desired effect in which the symptoms of the disorder are affected. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.

As described above, the agents disclosed herein can be administered together with other forms of therapy. For example, the molecules can be administered with antibodies, antibiotics, or other cancer treatment protocols as described above, or viral vectors. When the agent is in a vector, as described above, the vector containing the nucleic acid for therapeutic purposes can also contain the agent that modulates GSK-3 activity.

Kits

Disclosed herein are kits that are drawn to reagents that can be used in practicing the methods disclosed herein. The kits can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods. For example, the kits could include GSK-3, an inflammation inducing agent, and a suitable container. The kit can also include combinatorial libraries of small molecules. The kit can also include a screening platform, such as well plates for screening molecules.

The present invention is more particularly described in the following examples, which are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

Although the present process has been described with reference to specific details of certain embodiments thereof, it is not intended that such details should be regarded as limitations upon the scope of the invention except as and to the extent that they are included in the accompanying claims.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric.

EXAMPLES

Example 1: The PI3K Pathway Regulates Pro- vs. Anti-Inflammatory Cytokine Production

- 5 In an effort to identify if other well-defined TLR-agonists utilize the PI3K pathway to regulate pro- vs. anti-inflammatory cytokine production, as well as identify if a central downstream effector molecule is responsible for mediating the ability of this pathway to differentially dictate the host's inflammatory response, the use of protein-free *E. coli* LPS to stimulate human monocytes *in vitro* was employed.
- 10 Activation of PI3K can mediate the recruitment and subsequent activation of signaling proteins possessing pleckstrin homology domains, including the serine-threonine kinase Akt (Franke, 1997; Lawlor, 2001; Stokoe, 1997). After recruitment and activation, Akt becomes phosphorylated at Thr³⁰⁸ and Ser⁴⁷³ (Franke, 1997; Lawlor, 2001; Stokoe, 1997). Therefore, *E. coli* LPS activation of the PI3K-Akt pathway was
- 15 assessed (Fig. 1a). Assessment of Akt phosphorylation (ser⁴⁷³) demonstrated that *E. coli* LPS mediated the phosphorylation of Akt in which the PI3K inhibitor LY294002 abolished the ability of *E. coli* LPS to induce phosphorylation of Akt (Fig. 1a). Similar results were observed with the ability of *E. coli* LPS to induce the phosphorylation of Akt at Thr³⁰⁸.
- 20 Previous studies have shown that activated Akt is a key physiologic mediator of the PI3K pathway due to its ability to subsequently phosphorylate downstream targets, including the phosphorylation and subsequent inhibition of the serine/threonine kinase GSK-3 at position ser²¹ (GSK-3 β) and ser⁹ (GSK-3 α) (Cross, 1995). Thus, it was investigated if the phosphorylation status of the ubiquitously
- 25 expressed downstream kinase GSK-3 was being mediated by TLR4-stimulation of human monocytes in a PI3K-Akt-dependent manner. Human monocytes stimulated with *E. coli* LPS exhibited ser⁹ phosphorylation at multiple time points in which the PI3K inhibitor LY294002 abolished the ability of *E. coli* LPS to phosphorylate GSK-

3 β (Fig. 1b). A selective Akt inhibitor was then used to determine if this kinase was responsible for the phosphorylation of GSK-3 β by *E. coli* LPS (Fig. 1b). The ability of *E. coli* LPS to induce the phosphorylation of GSK-3 (ser⁹) was dependent upon Akt activity (Fig. 1b). Thus, the ability of the TLR4-signaling pathway to mediate the phosphorylation of GSK-3 β occurs via a PI3K-Akt dependent pathway.

Example 2: The Ability of the PI3K Pathway to Mediate the Phosphorylation and Inactivation of GSK-3 (ser⁹) Differentially Regulates the Ability of the TLR4-Signaling Pathway

To identify whether the ability of the TLR4-signaling pathway to engage GSK-3 β (ser⁹) was mediating a functional effect on the production of pro- and anti-inflammatory cytokine production by human monocytes, the levels of IL-10 and IL-12 were assessed in the presence of specific inhibitors for Akt (Akt-i), PI3K (LY294002), and GSK-3 (Lithium chloride or SB216763) (Fig. 2). The levels of the anti-inflammatory cytokine IL-10 were increased by more than 5-fold when human monocytes were stimulated with *E. coli* LPS in the presence of either lithium chloride (LiCl) or SB216763 (Fig. 2a). In contrast, inhibition of the PI3K pathway using LY294002 or Akt, both of which inhibited the ability of *E. coli* LPS to induce the phosphorylation of GSK-3 β (ser⁹) (Fig. 1), resulted in a severe reduction in IL-10 levels, as compared to *E. coli* LPS-treated monocytes (Fig. 2a). Moreover, assessment of IL-12 p40 production revealed that greater than a 80% reduction in IL-12 p40 levels were observed when human monocytes were stimulated in the presence of the GSK-3 inhibitor LiCl or SB216763 (Fig. 2b). In sharp contrast, IL-12 p40 levels were increased by more than 50% when LY294002 or the AKT inhibitor was employed (Fig. 2b). Thus, the ability of the PI3K pathway to mediate the phosphorylation and inactivation of GSK-3 (ser⁹) differentially regulates the ability of the TLR4-signaling pathway to induce classical pro- and anti-inflammatory cytokines by human monocytes (Fig. 2).

Example 3: The Role of GSK-3 in Differentially Controlling the Levels of Pro- and Anti-Inflammatory Cytokine Production

In order to define if the role of GSK-3 in differentially controlling the levels of pro- and anti-inflammatory cytokine production was strictly dependent upon TLR4 or
5 more globally evident among other TLR pathways, selective agonists for TLR2 (LTA from *S. pneumoniae*), TLR4 (synthetic lipid A; Compound 506), TLR5 (flagellin from *S. typhimurium*), and TLR9 (human CpG) were used, and it was assessed how inhibition of GSK-3 in conjunction with a specific TLR-agonist was affecting the inflammatory response by human PBMC. Using the GSK-3 inhibitor SB216763,
10 human PBMC stimulated with TLR2-, TLR4-, TLR5-, or TLR9-agonists exhibited a selective reduction of 50 to 90% (when SB216763 used at 5 to 10 μ M) in pro-inflammatory cytokine production, including IL-1 β , IL-6, IL-12 p40, and IFN- γ (Fig. 3a-d). In contrast, the levels of the anti-inflammatory cytokine IL-10 were increased by 3 to 8-fold as compared to control-treated cells (Fig. 3e). Similar effects on pro-
15 vs. anti-inflammatory cytokine profiles were also observed in cultures treated with the selective GSK-3 inhibitor LiCl when used at 1 to 10 mM. These data demonstrate that the ability of GSK-3 to selectively regulate the inflammatory response is well-conserved among the TLR-signaling pathway.

Example 4: Inhibition of GSK-3 *In Vivo* Can Differentially Control Pro- and Anti-Inflammatory Cytokine Production as well as Protect Mice from the Lethal Effects of LPS

Endotoxin is believed to be a key initiator of the early pro-inflammatory cascade that can mediate host tissue injury and lethal shock. The systemic inflammatory response that accompanies endotoxic shock is controlled by the levels
25 of pro- and anti-inflammatory cytokines. In this regard, the ability to suppress pro-inflammatory cytokines and/or enhance anti-inflammatory cytokines, i.e. IL-10, has been shown to severely reduce the toxic effects of endotoxin (Berg, 1995; Howard, 1993). Due to the present findings demonstrating the ability of GSK-3 to

differentially control pro- and anti-inflammatory cytokine production, inhibition of GSK-3 in a prophylactic manner was measured to determine if it could mediate protective effects in mice challenged with a lethal dose (LD₁₀₀) of LPS (Fig. 4a).

Administration of the GSK-3 inhibitor SB216763 2 hours before a LD₁₀₀ of LPS was

5 given to mice resulted in a severe abrogation of toxicity in which greater than 70% of the mice receiving the GSK-3 inhibitor SB216763 were protected from death, as compared to 0% in control-treated mice (Fig. 4a). Additionally, to investigate if a delayed administration of the GSK-3 inhibitor could be given to mice and still retain efficacy, giving mice SB216763 was delayed until 2 hours after the LD₁₀₀ of LPS (Fig. 10 4b). The delayed administration of SB216763 resulted in significant protection of mice from LPS-induced death in which approximately 55% of the mice survived, as compared to 0% of the control-treated mice (Fig. 4b). To rule out the possibility that GSK-3 inhibition simply extended the onset of LPS-induced lethality, both groups of mice (Fig. 4a, b) that received the GSK-3 inhibitor SB216763 and survived the LD₁₀₀ 15 of LPS were monitored over a 10-day period in which no late deaths were observed (Fig. 4). Assessment of the pro- and anti-inflammatory cytokine profiles from LPS-challenged mice receiving the LD₁₀₀ of LPS were also determined in order to characterize the nature of the inflammatory response *in vivo* (Fig. 5). Systemic levels of several pro-inflammatory cytokines were greatly reduced by more than 50% in mice 20 receiving the GSK-3 inhibitor SB216763, as compared to LPS-treated controls (Fig. 5a-c). In contrast, the *in vivo* production of IL-10 was increased by more than 2-fold in mice given SB216763, as compared to LPS-treated controls (Fig. 5d). Thus, inhibition of GSK-3 *in vivo* can differentially control pro- and anti-inflammatory cytokine production as well as protect mice from the lethal effects of LPS when 25 administered in a prophylactic or therapeutic manner.

A central mechanism has been characterized by which the inhibition of GSK-3 differentially affects the nature and magnitude of the inflammatory response. Inhibition of GSK-3 resulted in a profound increase in the levels of the anti-

inflammatory cytokine IL-10 upon TLR2-, TLR4-, TLR5-, and TLR9-activation whereas the concurrent production of pro-inflammatory cytokines including IL-1 β , IL-12, and IFN- γ were severely reduced by human monocytes and PBMC. These current findings identify a critical role for GSK-3 in modulating pro- vs. anti-inflammatory cytokines *in vivo* and provide a rationale to regulate the nature and severity of inflammation.

Example 5: General Methods

Mice and treatment with endotoxin (LPS)

C57BL/6 mice were bred and maintained within the pathogen-free animal facility at UAB. Experimental endotoxic shock was induced in age- and sex-matched C57BL/6 mice (18 to 23 g) by intraperitoneal injection of 150 μ g of LPS in PBS containing 0.1% DMSO. Mice pre-treated with the GSK-3 inhibitor SB216763 received 1 ml of PBS containing 30 μ M of SB216763 (DMSO was at 0.01%) by i.p. injection. LPS-control and sham-injected mice were pre-treated (i.p. injection) with 1ml of PBS containing 0.1% DMSO. Mice given the GSK-3 inhibitor SB216763 after LPS challenge received 1 ml of PBS containing 30 μ M of SB216763 (DMSO was at 0.01%) by i.p. injection. LPS-control and sham-injected mice were administered (i.p.) 1ml of PBS containing 0.01% DMSO. At 4 h after injection, blood from all groups of mice was obtained by retro-orbital plexus bleeding.

Reagents

Protein-free *E. coli* (K235) LPS were prepared as previously described (Hirschfeld, 2000; Hirschfeld, 2001). Lipoteichoic acid from *S. pneumoniae* used in the present study was purified as previously described (Han, 2003). Bacterial flagellin (*S. typhimurium*) was obtained from Dr. Gewirtz (Emory University, Atlanta, GA). *E. coli* synthetic lipid A (Compound 506) was obtained from Dr. Ogawa (Asahi University, Gifu, Japan). CpG (ODN 2216) 5'- ggGGGACGATCGTCgggggg -3' (SEQ ID NO: 5) and (ODN 2216 control) 5'- ggGGGAGCATGCTGcggggg -3' (SEQ ID NO: 6) were purchased from InvivoGen. Lithium chloride was purchased from

ATTORNEY DOCKET NO. 21085.0072U1

Sigma. The GSK-3 inhibitor SB216763 (Cross, 2001) was obtained from Tocris (Sydney, Australia). The Akt inhibitor II was purchased from Calbiochem (San Diego, CA). Antibodies against total p38, Akt (ser473), Akt (thr308), GSK-3 β (ser⁹), and total GSK-3 were purchased from Cell Signaling Technology.

5 *Measurement of cytokines*

Human or mouse IL-1 β , IL-10, IL-12 p40, and IFN- γ levels in the plasma of mice or cell-culture supernatants were determined by using enzyme-linked immunosorbent assay (ELISA) kits from R&D systems or Ebioscience according to manufacturer's instructions.

10 *Cell culture*

Heparinized venous blood from healthy donors was used to obtain PBMC by isolating the buffy coat and eliminating RBC contamination by histopaque (SG-1.077) density gradients. Human monocytes were purified from PBMC by negative selection using a monocyte isolation kit purchased from Miltenyi Biotec (Auburn, CA).

15 Monocytes were isolated from the PBMC by depletion of non-monocytic cells, which was performed with the aid of an indirect magnetic isolation kit using monoclonal hapten-conjugated CD3, CD7, CD19, CD45RA, CD56, and IgE antibodies (Miltenyi Biotec). This procedure routinely resulted in >95% pure CD14⁺ cells, as shown by flow cytometry. Human monocytes or PBMC were cultured in 24- (2 x 10⁶/well) or
20 96- (2 x 10⁵/well) well plates containing RPMI 1640 supplemented with 10% FBS, 50 μ M 2-ME, 1 mM sodium pyruvate, 2 mM L-glutamine, 20 mM HEPES, 50 U/ml penicillin, and 50 μ g/ml streptomycin. To assess the functional involvement of GSK-3 in TLR-induced cytokine production by monocytes or PBMC, cells were pre-treated
25 for 60 to 90 min with the PI3K inhibitor LY294002, Akt inhibitor II, LiCl, or SB216763 at the indicated concentrations. Control cells were pre-treated with culture media containing 0.01% DMSO (control for LY294002, Akt inhibitor, and SB216763) or 1 to 10 mM of NaCl (control for LiCl).

Statistical analysis

Data were expressed as the mean \pm SD. Statistical significance between groups was evaluated by ANOVA and the Tukey multiple-comparison test using the InStat program (GraphPad Software,). Differences between groups were considered
5 significant at the level of $P < 0.05$.

Throughout this application, various publications are referenced. The disclosures of these publications in their entirety are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

10

REFERENCES

1. Berg, D. J., K. Kuhn, K. Rajewsky, W. Muller, S. Menon, N. Davidson, G. Grunig, and D. Rennick 1995. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance J. Clin. Invest. 96:2339-2347.
2. Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature. 378:785-789.
3. Cross, D. A., A. A. Culbert, K. A. Chalmers, L. Facci, S. D. Skaper, and A. D. Reith 2001. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death J. Neurochem. 77:94-102.
4. Dinarello, C. A. 2000. Proinflammatory cytokines Chest. 118:503-508.
5. Franke, T. F., D. R. Kaplan, L. C. Cantley, and A. Toker 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate Science. 275:665-668.
6. Fukao, T., M. Tanabe, Y. Terauchi, T. Ota, S. Matsuda, T. Asano, T. Kadowaki, T. Takeuchi, and S. Koyasu 2002. PI3K-mediated negative feedback regulation of IL-12 production in DCs Nat. Immunol. 3:875-881.
7. Fukao, T., T. Yamada, M. Tanabe, Y. Terauchi, T. Ota, T. Takayama, T. Asano, T. Takeuchi, T. Kadowaki, J. J. Hata, and S. Koyasu 2002. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol. 3:295-304.
8. Guha, M., and N. Mackman 2002. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells J. Biol. Chem. 277:32124-32132.
9. Han, S. H., J. H. Kim, M. Martin, S. M. Michalek, and M. H. Nahm 2003.

ATTORNEY DOCKET NO. 21085.0072U1

- Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2 Infect. Immun. 71:541-5548.
10. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2 J. Immunol. 165:18-22.
 11. Hirschfeld, M., J. J. Weis, V. Toshchakov, C. A. Salkowski, M. J. Cody, D. C. Ward, N. Qureshi, S. M. Michalek, and S. N. Vogel 2001. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages Infect. Immun. 69:1477-1482.
 12. Howard, M., T. Muchamuel, S. Andrade, and S. Menon 1993. Interleukin 10 protects mice from lethal endotoxemia J. Exp. Med. 177:1205-1208.
 13. Lawlor, M. A., and D. R. Alessi 2001. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell. Sci. 114:2903-2910.
 14. Martin, M., R. E. Schifferle, N. Cuesta, S. N. Vogel, J. Katz, and S. M. Michalek 2003. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by *Porphyromonas gingivalis* lipopolysaccharide J. Immunol. 171:717-725.
 15. O'Neill, L. A., and C. A. Dinarello 2000. The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense Immunol. Today. 21:206-209.
 16. Stokoe, D. L. R., L. R. Stephens, T. Copeland, R. Piers, J. Gaffney, C. B. Reese, G. F. Painter, A. B. Holmes, F. McCormick, and P. T. Hawkins 1997. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B Science. 277:567-570.
 17. Tapping, R. I., S. Akashi, K. Miyake, P. J. Godowski, and P. S. Tobias 2000. Toll-like receptor 4, but not Toll-like receptor 2, is a signaling receptor for *Escherichia* and *Salmonella* lipopolysaccharides J. Immunol. 165:5780-5787.
 18. Jooss, K. (2003) Gene Ther. 10:955-963; Zaiss, A.K. (2002) J. Virol. 76:4580-4590
 19. Walport, M.J. (2001) N Eng J Med 344:1058-1066 and 1140-1144

ATTORNEY DOCKET NO. 21085.0072U1

20. Cichon (2001) *Gene Ther* 8:1794-1800
21. Feghali et al. *Frontiers in Bioscience* 2, d12-26, January 1, 1997
22. Prescilla et al. <http://www.emedicine.com>, Immunology of Transplant Rejection, updated June 20, 2003
23. Sambrook, et al., 1989, In: *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York
24. Harris, et al., *Fundam. Appl. Toxicol.* 19:186-196
25. Brigham et al. *Am. J. Resp. Cell. Mol. Biol.* 1:95-100 (1989)
26. Felgner et al. *Proc. Natl. Acad. Sci USA* 84:7413-7417 (1987)
27. U.S. Pat. No.4,897,355
28. Senter, et al., *Bioconjugate Chem.*, 2:447-451, (1991)
29. Bagshawe, K.D., *Br. J. Cancer*, 60:275-281, (1989)
30. Bagshawe, et al., *Br. J. Cancer*, 58:700-703, (1988)
31. Senter, et al., *Bioconjugate Chem.*, 4:3-9, (1993)
32. Battelli, et al., *Cancer Immunol. Immunother.*, 35:421-425, (1992)
33. Pietersz and McKenzie, *Immunolog. Reviews*, 129:57-80, (1992); and Roffler, et al., *Biochem. Pharmacol*, 42:2062-2065, (1991)
34. Brown and Greene, *DNA and Cell Biology* 10:6, 399-409 (1991)

ATTORNEY DOCKET NO. 21085.0072U1

What is claimed is:

1. A method of reducing the severity of inflammation in a subject comprising:
 - a. selecting a subject with inflammation or at risk for inflammation and
 - b. administering to the subject an effective amount of an agent that inhibits glycogen synthase kinase 3 activity, inhibition of glycogen synthase kinase 3 reducing the severity of inflammation in the subject.
2. The method of claim 1, wherein the agent is administered within 24 hours before or after the subject is contacted with an inflammatory agent.
3. The method of claim 2, wherein the agent is administered within 2 hours before or after the subject is contacted with an inflammatory agent.
4. The method of claim 2, wherein the agent is administered within 2 hours before or after inflammation begins.
5. The method of claim 1, wherein the inflammation is associated with an infection.
6. The method of claim 5, wherein the infection is a viral infection.
7. The method of claim 5, wherein the infection is a bacterial infection.
8. The method of claim 7, wherein the bacterial infection is a gram positive bacterial infection.
9. The method of claim 7, wherein the bacterial infection is a gram negative bacterial infection.
10. The method of claim 1, wherein the agent is lithium chloride.
11. The method of claim 1, wherein the agent is SB216763.
12. The method of claim 1, wherein the inflammation is sepsis.
13. The method of claim 1, wherein the agent is administered to the subject prior to or after surgery.
14. The method of claim 1, wherein the agent is administered to the subject prior to or after contact with an infectious biological weapon.
15. A method of reducing the severity of inflammation in a subject comprising:

ATTORNEY DOCKET NO. 21085.0072U1

- a. selecting a subject with inflammation or at risk for inflammation and
 - b. administering to the subject an effective amount of an agent that inhibits phosphorylation of glycogen synthase kinase 3 activity, inhibition of phosphorylation of glycogen synthase kinase 3 reducing the severity of inflammation in the subject.
16. The method of claim 15, wherein the agent mediates the phosphorylation of serine at the ninth or twenty first residue of glycogen synthase kinase 3.
17. The method of claim 16, wherein the agent is lithium chloride.
18. The method of claim 16, wherein the agent is SB216763.
19. A method of reducing the severity of inflammation in a biological system comprising:
- a. selecting an inflamed biological system or a biological system at risk for inflammation and
 - b. administering to the biological system an effective amount of an agent that inhibits glycogen synthase kinase 3, inhibition of glycogen synthase kinase 3 reducing the severity of inflammation in the biological system.
20. The method of claim 19, wherein the biological system is an *in vitro* or *ex vivo* culture system.
21. The method of claim 19, wherein the biological system is a tissue culture system.
22. The method of claim 19, wherein the biological system is an organ culture system.
23. A method of reducing the severity of inflammation in a biological system comprising:
- a. selecting an inflamed biological system or a biological system at risk for inflammation and

ATTORNEY DOCKET NO. 21085.0072U1

- b. administering to the biological system an effective amount of an agent that modulates phosphorylation of glycogen synthase kinase 3, modulation of phosphorylation of glycogen synthase kinase 3 reducing the severity of inflammation in the biological system.
- 24. A method of reducing the severity of inflammation in a subject comprising:
 - a. selecting a subject with inflammation or at risk for the inflammation and
 - b. administering to the subject an effective amount of an agent that inhibits phosphorylation of glycogen synthase kinase 3, inhibition of phosphorylation reducing the severity of the inflammation in the subject.
- 25. The method of claim 24, wherein the inflammation is associated with an inflammatory disease.
- 26. The method of claim 25, wherein the inflammatory disease is selected from he group consisting of systemic lupus erythematosus, Hashimoto's disease, rheumatoid arthritis, graft-versus-host disease, Sjögren's syndrome, pernicious anemia, Addison disease, scleroderma, Goodpasture's syndrome, Crohn's disease, autoimmune hemolytic anemia, myasthenia gravis, multiple sclerosis, Basedow's disease, thrombopenia purpura, insulin-dependent diabetes mellitus, allergy; asthma, inflammatory bowel disease, cancer, ulcerative colitis, scleroderma, and cardiomyopathy.
- 27. A method of reducing the risk of inflammation in a recipient of an implantation or a transplantation comprising contacting the implant or transplant with an agent that inhibits glycogen synthase kinase 3 activity, inhibition of glycogen synthase kinase 3 activity reducing the risk of inflammation of the recipient.
- 28. The method of claim 27, wherein the contacting step is performed prior to implantation or transplantation into the recipient.

ATTORNEY DOCKET NO. 21085.0072U1

29. A method of reducing the risk of inflammation in a recipient of an implantation or a transplantation comprising contacting the implant or transplant with an agent that modulates phosphorylation of glycogen synthase kinase 3 activity, modulation of phosphorylation of glycogen synthase kinase 3 activity reducing the risk of inflammation of the recipient.

ABSTRACT

This invention relates generally to a method of treating inflammation and associated diseases and disorders by administering an agent that inhibits glycogen
5 synthase kinase 3 activity.

FIG. 1





FIG. 2






FIG. 3a




FIG. 3b




FIG. 3c

D




FIG. 3d








FIG. 3e

—□— Sham-injected
 —■— LPS
 —▤— LPS + SB216763
 —△— SB216763



—□— Sham-injected
 —■— LPS
 —▤— LPS + SB216763
 —△— SB216763




FIG. 4







FIG. 5





FIG. 6

SEQUENCE LISTING

<110> MARTIN, Michael

<120> Methods and Compositions Related to
Regulation of Cytokine Production by Glycogen Synthase
Kinase 3 (GSK-3)

<130> 21085.0072U1

<140> Unassigned

<141> 2004-03-04

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 483

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; note =
synthetic construct

<400> 1

Met	Ser	Gly	Gly	Gly	Pro	Ser	Gly	Gly	Gly	Pro	Gly	Gly	Ser	Gly	Arg
1				5					10					15	
Ala	Arg	Thr	Ser	Phe	Ala	Glu	Pro	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly
			20				25						30		
Gly	Gly	Gly	Pro	Gly	Gly	Ser	Ala	Ser	Gly	Pro	Gly	Gly	Thr	Gly	Gly
		35					40					45			
Gly	Lys	Ala	Ser	Val	Gly	Ala	Met	Gly	Gly	Gly	Val	Gly	Ala	Ser	Ser
	50					55					60				
Ser	Gly	Gly	Gly	Pro	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Pro
65					70					75					80
Gly	Ala	Gly	Thr	Ser	Phe	Pro	Pro	Pro	Gly	Val	Lys	Leu	Gly	Arg	Asp
				85					90					95	
Ser	Gly	Lys	Val	Thr	Thr	Val	Val	Ala	Thr	Leu	Gly	Gln	Gly	Pro	Glu
			100					105					110		
Arg	Ser	Gln	Glu	Val	Ala	Tyr	Thr	Asp	Ile	Lys	Val	Ile	Gly	Asn	Gly
		115					120					125			
Ser	Phe	Gly	Val	Val	Tyr	Gln	Ala	Arg	Leu	Ala	Glu	Thr	Arg	Glu	Leu
	130					135					140				
Val	Ala	Ile	Lys	Lys	Val	Leu	Gln	Asp	Lys	Arg	Phe	Lys	Asn	Arg	Glu
145					150					155					160
Leu	Gln	Ile	Met	Arg	Lys	Leu	Asp	His	Cys	Asn	Ile	Val	Arg	Leu	Arg
			165						170					175	
Tyr	Phe	Phe	Tyr	Ser	Ser	Gly	Glu	Lys	Lys	Asp	Glu	Leu	Tyr	Leu	Asn
			180					185					190		
Leu	Val	Leu	Glu	Tyr	Val	Pro	Glu	Thr	Val	Tyr	Arg	Val	Ala	Arg	His
		195					200					205			
Phe	Thr	Lys	Ala	Lys	Leu	Thr	Ile	Pro	Ile	Leu	Tyr	Val	Lys	Val	Tyr
	210					215					220				
Met	Tyr	Gln	Leu	Phe	Arg	Ser	Leu	Ala	Tyr	Ile	His	Ser	Gln	Gly	Val
225					230					235					240
Cys	His	Arg	Asp	Ile	Lys	Pro	Gln	Asn	Leu	Leu	Val	Asp	Pro	Asp	Thr
			245						250					255	
Ala	Val	Leu	Lys	Leu	Cys	Asp	Phe	Gly	Ser	Ala	Lys	Gln	Leu	Val	Arg

[illegible]

```
<210> 3
<211> 2189
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence; note =
        synthetic construct
```

<400> 3							
gcggcgcgccg	ctggaagagg	ccaggggccc	ggggaggcgg	cggcagcgcc	ggcggtctggg		60
gcagcccggg	cagcccgagc	cccgagccct	gggcctgtgc	tcggcgccat	gagcggcggc		120
gggccttcgg	gaggcgccc	tgggggctcg	ggcaggcgcg	ggactagctc	gttcgcggag		180
cccggcgggc	gaggcggagg	aggcggcggc	ggccccggag	gctcggcctc	cggcccaggc		240
ggcaccggcg	gcggaaagcg	atctgtcggg	gccatgggtg	ggggcgctcg	ggcctcgagc		300
tccgggggtg	gaccgcggcg	cagcggcgga	ggaggcagcg	gaggccccgg	cgcaggcact		360
gacttccgcg	cgcccggggt	gaagctgggc	cgtagacagc	ggaaggtgac	cacagtcgta		420
gccactctag	gccaaggccc	agagcgctcc	caagaagtgg	cttacacgga	catcaaagtg		480
attggcaatg	gctcatttgg	ggtcgtgtac	caggcacggc	tggcagagac	cagggaacta		540
gtcgccatca	agaaggttct	ccaggacaag	aggttcaaga	accgagagct	gcagatcatg		600
cgtaagctgg	accactgcaa	tattgtgagg	ctgagatact	ttttctactc	cagtggcgag		660
aagaaagacg	agctttacct	aaatctgggt	ctggaatatg	tgcccagagac	agtgtaccgg		720
gtggccccgc	acttcaccaa	ggccaagtta	accatcccta	tcctctatgt	caagggtgac		780
atgtaccagc	tcttcgcgag	cttggcctac	atccactccc	agggcgatgt	tcacgcggac		840
atcaagcccc	agaacctgct	ggtggacctc	gacactgctg	tcctcaagct	ctcgattttt		900
ggcagtgcaa	agcagttggt	ccgagggggag	cccaatgtct	cctacatctg	ttctcgctac		960

taccggggccc	cagagctcat	ctttggagcc	actgattaca	cctcatccat	cgatgtttgg	1020
tcagctggct	gtgtactggc	agagctcctc	ttggggccagc	ccatcttccc	tggggacagt	1080
ggggtggacc	agctggtgga	gatcatcaag	gtgctgggaa	caccaaccgg	ggaacaaatc	1140
cgagagatga	accccaacta	cacggagttc	aagttccctc	agattaaagc	tcacccctgg	1200
acaaagggtgt	tcaaattctcg	aacgccgcca	gaggccatcg	cgctctgctc	tagcctgctg	1260
gagtacaccc	catcctcaag	gctctcccca	ctagaggcct	gtgcgcacag	cttctttgat	1320
gaactgcgat	gtctgggaac	ccagctgcct	aacaaccgcc	cacttcccc	tctcttcaac	1380
ttcagtgtcg	gtgaactctc	catccaaccg	tctctcaacg	ccattctcat	ccctcctcac	1440
ttgagggtccc	cagcgggcac	taccaccctc	accccgctct	cacaagcttt	aactgagact	1500
ccgaccagct	cagactggca	gtcgaccgat	gccacacctc	ccctcactaa	ctcctcctga	1560
gggccccacc	aagcaccctt	ccacttccat	ctggggagccc	caagagggggc	tgggaagggg	1620
ggccatagcc	catcaagctc	ctgcccctggc	tggggccccta	gactagaggg	cagaggtaaa	1680
tgagtcctgt	tcccacctc	cagtcctctc	ctcaccagcc	tcacccctgt	gggtgggcttt	1740
ttaaagaggat	tttaactggg	tgtggggagg	gaagagaagg	acagggtgtt	ggggggatga	1800
ggacctccta	cccccttggc	cccctccctt	ccccagacc	tccacctcct	ccagaccccc	1860
tcccctcctg	tgteccctgt	aaatagaacc	agcccagccc	gtctcctctt	cccttccctg	1920
gcccccggt	gtaaatagat	tgttataatt	tttttcttaa	agaaaacgtc	gattcgcacc	1980
gtccaacctg	gccccgcccc	tcttacagct	gtaactcccc	tctgtcctc	tgcccccaag	2040
gtctactccc	tcttcacccc	accctggagg	gccagggggag	tggagagagc	tcctgatgtc	2100
ttagtttcca	cagtaagggt	tgctgtgtga	cagacctccg	ttcaataaat	tattggcatg	2160
aaaacctgaa	aaaaaaaaaa	aaaaaaaaaa				2189

<210> 4

<211> 1639

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; note =
synthetic construct

<400> 4

atcatctata	tgttaaatat	ccgtgccgat	ctgtcttgaa	ggagaaatat	atcgcttggt	60
ttgtttttta	tagtatacaa	aaggagtga	aagccaagag	gacgaagtct	ttttcttttt	120
cttctgtggg	agaacttaat	gctgcattta	togttaacct	aacaccccaa	cataaagaca	180
aaaggaagaa	aaggaggaag	gaaggaaaag	gtgattcgcg	aagagagtga	tcatgtcagg	240
gcggcccaga	accacctcct	ttgcggagag	ctgcaagccg	gtgcagcagc	cttcagcttt	300
tggcagcatg	aaagttagca	gagacaagga	cggcagcaag	gtgacaacag	tgggtggcaac	360
tcctgggcag	ggtccagaca	ggccacaaga	agtcagctat	acagacacta	aagtgtattg	420
aaatggatca	tttgggtgtg	tatatcaagc	caaactttgt	gattcaggag	aactggctgc	480
catcaagaaa	gtattgcagg	acaagagatt	taagaatcga	gagctccaga	tcatgagaaa	540
gctagatcac	tgtaacatag	tccgattgcg	ttattttctt	tactccagtg	gtgagaagaa	600
agatgaggtc	tatcttaatc	tgggtgctga	ctatgttccg	gaaacagtat	acagagttgc	660
cagacactat	agtcgagcca	aacagacgct	ccctgtgatt	tatgtcaagt	tgtatatgta	720
tcagctgttc	cgaagtttag	cctatatcca	ttcctttgga	atctgccatc	gggatattaa	780
accgcagaac	ctcttggttg	atcctgatac	tgctgtatta	aaactctgtg	actttggaag	840
tgcaaagcag	ctggtccgag	gagaacccaa	tgtttcgtat	atctgttctc	ggtactatag	900
ggcaccagag	ttgatctttg	gagccactga	ttatacctct	agtatagatg	tatggtctgc	960
tggctgtgtg	ttggctgagc	tggtactagg	acaaccaata	tttccagggg	atagtgggtg	1020
ggatcagttg	gtagaaataa	tcaaggctct	gggaactcca	acaagggagc	aaatcagaga	1080
aatgaaccca	aactacacag	aatttaaatt	ccctcaaatt	aaggcacatc	cttggaactaa	1140
ggattcgta	ggaacaggac	atttcacctc	aggagtgcgg	gtcttccgac	cccgaactcc	1200
accggaggca	attgcactgt	gtagccgtct	gctggagtat	acaccaactg	cccgaactaac	1260
accactggaa	gcttgtgcac	attcattttt	tgatgaatta	cgggacccaa	atgtcaaact	1320
accaaattgg	cgagacacac	ctgcaactct	caacttcacc	actcaagaac	tgtcaagtaa	1380
tccacctctg	gctaccatcc	ttattcctcc	tcatgctcgg	attcaagcag	ctgcttcaac	1440
ccccacaaat	gccacagcag	cgtcagatgc	taatactgga	gaccgtggac	agaccaataa	1500
tgctgcttct	cgatcagctt	ccaactccac	ctgaacagtc	ccgagcagcc	agctgcacag	1560
gaaaaaccac	cagttacttg	agtgctcactc	agcaacactg	gtcacgtttg	gaaagaatat	1620
taaaaaaaaa	aaaaaaaaaa					1639

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; note =
synthetic construct

<400> 5
gggggacgat cgtcggggggg

20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; note =
synthetic construct

<400> 6
gggggagcat gctgcggggg

20